New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness

Isabel Corraliza-Gorjón¹, Beatriz Somovilla-Crespo¹, Silvia Santamaria², Jose A. Garcia-Sanz²*† and Leonor Kremer¹*†

¹Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain, ²Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CIB-CSIC), Madrid, Spain

Antibodies have proven their high value in antitumor therapy over the last two decades. They are currently being used as the first-choice to treat some of the most frequent metastatic cancers, like HER2+ breast cancers or colorectal cancers, currently treated with trastuzumab (Herceptin) and bevacizumab (Avastin), respectively. The impressive therapeutic success of antibodies inhibiting immune checkpoints has extended the use of therapeutic antibodies to previously unanticipated tumor types. These anti-immune checkpoint antibodies allowed the cure of patients devoid of other therapeutic options, through the recovery of the patient’s own immune response against the tumor. In this review, we describe how the antibody-based therapies will evolve, including the use of antibodies in combinations, their main characteristics, advantages, and how they could contribute to significantly increase the chances of success in cancer therapy. Indeed, novel combinations will consist of mixtures of antibodies against either different epitopes of the same molecule or different targets on the same tumor cell; bispecific or multispecific antibodies able of simultaneously binding tumor cells, immune cells or extracellular molecules; immunomodulatory antibodies; antibody-based molecules, including fusion proteins between a ligand or a receptor domain and the IgG Fab or Fc fragments; autologous or heterologous cells; and different formats of vaccines. Through complementary mechanisms of action, these combinations could contribute to elude the current limitations of a single antibody which recognizes only one particular epitope. These combinations may allow the simultaneous attack of the cancer cells by using the help of the own immune cells and exerting wider therapeutic effects, based on a more specific, fast, and robust response, trying to mimic the action of the immune system.

Keywords: cancer, antibody combinations, oncology, therapeutic antibodies, immunotherapy

INTRODUCTION

Nowadays, the therapeutic activity of antibodies in oncology has been widely demonstrated (1–6), being these proteins, after chemotherapy, radiotherapy, and small molecule inhibitors, one of the most used drugs for oncological treatments (7, 8). Most of the antibodies used on antitumor immunotherapies had positive health effects as long as the antibody is present in the patient’s blood. The clinical use of antibodies directed against antigens not present on the tumor cells, but on cells of the immune
The aim of this review is to discuss the information on the possible anti-cancer treatments using monoclonal antibodies (mAbs; in clinical trials or already in the market) in combinations, either with other antibodies or with other biological agents (11–18). The clinical trials are mentioned throughout this review only as examples of the different types of combinations being currently analyzed for cancer treatment. Thus, for most of the studies details and results will be shown on Supplementary Tables S1 and S2. The use of radiation therapy, chemotherapy, small-molecule compounds, or stem cell autotransplants will be mentioned only, if the information is strictly necessary in our attempt to dissect the reasons behind the use of these combinations. Similarly, there is no specific section describing combinations including checkpoint inhibitory mAbs, since this subject has been recently reviewed (19–24), including the reviews by Xu-Monette and Young and Aris et al., in this issue (25, 26). Similarly, combinations directed against cancer stem cells will not be discussed since they have been treated elsewhere in this research topic (27).

Antibodies are generated by the immune system's adaptive arm to defend the organism from pathogens and malignant cells. The antibodies are basically secreted molecules involved in mediating interactions on the extracellular compartment; they are made by a variable part that gives its binding specificity, and a constant region that is able to interact with other molecules or cells of the innate and adaptive immune system, to give them molecular information regarding their interaction with antigen. Thus, it should come to no surprise that antibodies' functions promote health and that treatments based on antibodies might, therefore, be curative (6, 28, 29).

Very few therapeutic antibodies are able to directly kill the tumor cells, either by interacting with a signal pathway (i.e., as a receptor antagonist or sequestering the ligand), or by direct triggering of apoptosis. Most of them kill the tumor cells through the interaction with other molecules or cells of the immune system, acting as molecules mediating interactions on the extracellular compartment. Although they originated as receptors on the surface of cells from the acquired immune system, they became secreted on mature B cells, and through either engagement with Fc-receptor-bearing cells or by interaction with the complement system, they can exert a broad spectrum of effector functions, coordinating the immune response (see Figure 1).

A current goal of antitumor immune therapies is to trigger, from the beginning, all the possible host body defense mechanisms. Aiming to destroy, as early as possible, the highest number of tumor cells, decreasing the possibilities of the tumor developing escape mechanisms, to obtain a more effective therapy. The defense mechanisms include (i) to directly kill the tumor cells; (ii) to switch the immune system from an antitumor immunosuppressed status to another that allows to attack the tumor, i.e., through stimulating the secretion of cytokines or modulating cell to cell interactions; (iii) to attract the immune system cells to the tumor; (iv) to decrease the tumor-directed neo-vascularization; and (v) to inhibit migration, metalloprotease secretion, and tumor cell invasion, among others.

The current trends for the use of antibodies in oncology as therapeutic agents are to employ them either alone or, more often, as combinations with (i) cytotoxic agents; (ii) radiotherapy; (iii) molecularly targeted drugs interfering with tumor cell survival or proliferation; (iv) other antibodies against the same target; (v) other antibodies against molecules implicated in the same signaling pathway; (vi) other antibodies, each one of them specific for unrelated targets (including targets in immune system cells and neo-vascularization); (vii) vaccines or oncolytic virus; (viii) cells that would either act as immunogens or as effector cells; or (ix) adjuvants, liposomes, nanoparticles, etc.

For the treatment of cancer, the FDA and the EMA (United States and European Union Drug Administrations), have approved (or are reviewing) a total of 32 therapeutic antibodies or their derivatives. Interestingly, the number has doubled between 2012 and 2017 (Tables 1 and 2), concomitant with a 100% increase in phase III clinical trials using mAb on a similar time-period (30). Twenty of these antibodies are indicated for treatment of patients with solid tumors (Table 1), identifying 13 different targets; whereas 12 are indicated for neoplasias of hematological origin (Table 2), identifying eight different targets. The targets identified by these antibodies are described in Table 3. Other therapeutic...
| Approved indications | Target | International non-proprietary name | Brand name | Format | Proposed mechanism(s) of action | EU/US First approval year | Sponsor | Reference |
|----------------------|--------|-----------------------------------|------------|--------|---------------------------------|---------------------------|---------|-----------|
| Soft tissue sarcoma  | PDGFRα | Olaratumab                         | Lartruvo   | Human IgG1 | Binds to PDGFR-α, blocks ligand binding and receptor signaling | 2016/2016 | Eli Lilly and Co. | (31–34)   |
| Breast cancer        | HER2   | Pertuzumab                         | Perjeta    | Humanized IgG1 | Inhibits HER dimerization, prevents the formation of ligand-induced heterodimers of HER2 with other family members. Induces ADCC | 2013/2012 | Genentech | (35–38) |
| Breast cancer and gastric cancer | HER2 | Trastuzumab | Herceptin | Humanized IgG1 | Inhibits HER dimerization, prevents the formation of ligand-induced heterodimers of HER2 with other family members. Induces ADCC and phagocytosis | 2000/1998 | Genentech | (39–43) |
| Breast cancer        | HER2   | Ado-trastuzumab emtansine          | Kadcyla    | Humanized IgG1 conjugated to emtansine (ADC) | Inhibits HER dimerization, prevents the formation of ligand-induced heterodimers of HER2 with other family members. Induces ADCC and phagocytosis. Transports emtansine (microtubule inhibitor) to HER2-positive tumors | 2013/2013 | Genentech | (44–47) |
| HNSCC                | Epidermal growth factor receptor (EGFR) | Necitumumab | Portrazza | Human IgG1 | Binds to EGFR, blocks ligand binding and triggers EGFR internalization and degradation. Induces ADCC | 2015/2015 | Eli Lilly and Co. | (48–53) |
| Colorectal cancer    | EGFR   | Panitumumab                        | Vectibix   | Human IgG2 | Binds to EGFR, competitively inhibits the binding of its ligands, blocking receptor signaling | 2007/2006 | Amgen | (54–58) |
| HNSCC, Colorectal cancer | EGFR | Cetuximab                         | Erbitux    | Chimeric IgG1 | Binds to EGFR, blocks ligand binding and triggers EGFR internalization and degradation. Induces ADCC | 2004/2004 | ImClone LLC | (59–63) |
| Breast cancer, colorectal cancer, non-squamous NSCLC, RCC, cervix carcinoma, ovarian or fallopian tube cancer, primary peritoneal cancer, and glioblastoma | VEGFA | Bevacizumab | Avastin | Humanized IgG1 | Binds to VEGFA, prevents interaction with its receptors and their subsequent activation | 2005/2004 | Genentech | (64–68) |
| NSCLC, gastric cancer, and colorectal cancer | VEGFR2 | Ramucirumab | Cyramza | Human IgG1 | Binds to VEGFR2, inhibits the binding of its ligands, blocking receptor signaling | 2014/2014 | Eli Lilly and Co. | (69–73) |
| NSCLC and urothelial carcinoma | PD-L1 | Atezolizumab | Tecentriq | Humanized IgG1 | Blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80. Blocks the immune checkpoint inhibition. Contains a modified Fc region to limit ADCC or CDC | 2017/2016 | Genentech | (74–78) |
| Urothelial carcinoma | PD-L1 | Durvalumab                         | Imfinzi    | Human IgG1 | Blocks the interaction of PD-L1 with PD-1 and CD80. Blocks the immune checkpoint inhibition. Does not induce ADCC | NAV2017 | AstraZeneca | (79–82) |

(Continued)
| Approved indications | Target | International non-proprietary name | Brand name | Format | Proposed mechanism(s) of action | EU/US First approval year | Sponsor | Reference |
|----------------------|--------|-----------------------------------|------------|--------|--------------------------------|--------------------------|---------|-----------|
| Merkel cell carcinoma | PD-L1  | Avelumab                          | Bavencio   | Human IgG1 | Blocks the interaction of PD-L1 with PD-1 and CD80. Blocks the immune checkpoint inhibition | 2017+/2017 | Merck/Pfizer | (83–86) |
| Melanoma, RCC, NSCLC, HNSCC, chHL and urothelial carcinoma | PD-1   | Nivolumab                         | Opdivo     | Human IgG4 | Binds to PD-1, blocks its interaction with PD-L1 and PD-L2. Blocks the immune checkpoint inhibition. Does not induce ADCC | 2015/2014 | Ono Pharma (Japan)/Bristol-Myers Squibb (Worldwide) | (87–91) |
| Melanoma, NSCLC, HNSCC, and chHL | PD-1   | Pembrolizumab                     | Keytruda   | Humanized IgG4 | Binds to PD-1, blocks its interaction with PD-L1 and PD-L2. Blocks the immune checkpoint inhibition. Does not induce ADCC | 2015/2014 | Merck | (92–96) |
| Melanoma | CTLA-4 | Ipilimumab                        | Yervoy     | Human IgG1 | Binds to CTLA-4, blocks its interaction with CD80 and CD86, increasing T cell activation and proliferation | 2011/2011 | Bristol-Myers Squibb | (97–100) |
| Bone metastases from solid tumors, Increase of bone mass | RANK-L | Denosumab                         | Prolia     | Human IgG2 | Binds to RANK-L, blocks its interaction with RANK, and prevents bone loss | 2010/2010 | Amgen | (101–105) |
| Colorectal cancer | IL-1α  | MA2bP1 | Xilonix | Human IgG1 | Binds to IL-1α, blocks its interaction with IL-1-R | In review/NA | XBiotech | (106–108) |
| Neuroblastoma | GD2    | Dinutuximab                       | Unituxin   | Chimeric IgG1 | Binds to the TAA GD2. Activates CDC and ADCC | 2015+/2015 | United Therapeutics | (109–112) |
| EpCAM⁺-Colon cancer | EpCAM  | Edrecolomab                       | Panorex    | Murine IgG2a | Engages immune effector cells. Activates CDC, ADCC, and phagocytosis | 1995+/NA | GlaxoSmith Kline | (113–116) |
| EpCAM⁺-carcinomas related ascites | EpCAM/CD3 | Catumaxomab                     | Removab    | Rat/mouse bispecific monoclonal antibody | Attracts immune cells to the tumor proximity, promoting T cell activation and effector functions. Activates CDC, ADCC and phagocytosis | 2009+/NA | Trion Pharma/Biotech | (117–121) |

*Adapted from Janice M. Reichert, PhD, The Antibody Society; last update July, 2017.
ADCC, antibody–drug conjugate; ADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent cytotoxicity; chHL, classical Hodgkin lymphoma; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; TAA, tumor-associated antigen.
*Country-specific approval, 20 July 2017.
*International non-proprietary name pending.
*EMA initial authorization.
*Withdrawn or marketing discontinued for the first approved indication.
NA, not approved or in review in the EU, not approved or information on review status not available in the US.
Color shades corresponds to structurally related target molecules.
| Approved indication | Target | International non-proprietary name | Brand name | Format | Proposed mechanism(s) of action | EU/US First approval year | Sponsor | Reference |
|---------------------|--------|-----------------------------------|------------|--------|---------------------------------|--------------------------|---------|-----------|
| ALL                 | CD19/CD3 | Blinatumomab | Blincyto | Murine bispecific tandem scFv | Binds CD19 on tumor B cells and puts them in close contact with T cells through the CD3 (TCR complex), activates them, and results in redirected tumor cell lysis | 2015/2014 | Amgen | (122–126) |
| CLL and follicular lymphoma | CD20 | Obinutuzumab | Gazyva | Humanized IgG1; Glycoengineered | Lyses B cells by effector-cell recruitment. Enhanced CDC, ADCC, and ADCP, contains a modified Fc region with increased binding affinity for FcgammaRIII. Mutation (R7159) enhances apoptosis | 2014/2013 | Roche | (127–132) |
| CLL                 | CD20 | Ofatumumab | Arzerra | Human IgG1 | Binds to CD20 and engages immune effector cells, mediates B-cell lysis. Activates CDC, ADCC, and ADCP | 2010/2009 | Novartis | (133–136) |
| NHL                 | CD20 | Tositumomab-tixetan | Bexxar | Murine IgG2a linked to ^131I | Binds to CD20 and engages immune effector cells, mediates B-cell lysis. Activates CDC, ADCC, and ADCP, induces apoptosis. Ionizing radiation kills CD20+ cells | NA/2003 | GlaxoSmithKline | (137–140) |
| NHL                 | CD20 | Ibritumomab-tuxetan | Zevalin | Murine IgG1 linked to ^90Y-tuxetan | Binds to CD20, the tuxetan moiety binds ^90Y, the beta emission induces cell damage. Activates CDC, ADCC, and apoptosis | 2004/2002 | Spectrum Pharmaceuticals | (141–144) |
| NHL and CLL        | CD20 | Rituximab | MabThera-Rituxan | Chimeric IgG1 | Binds to CD20 and engages immune effector cells, mediates B-cell lysis. Activates CDC, ADCC ,and ADCP | 1998/1997 | Roche Biogen/Genentech | (145–150) |
| ALL                 | CD22 | Inotuzumab ozogamicin | Besponsa | Humanized IgG4 linked to N-acetyl-gamma-calicheamicin (ADC) | Binds to CD22+ cells. After internalization, the toxin induces double-stranded DNA breaks and apoptosis | 2017/2017 | Pfizer | (151–155) |
| Hodgkin lymphoma and systemic anaplastic large cell lymphoma | CD30 | Brentuximab vedotin | Adcetris | Chimeric IgG1 linked to monomethyl auristatin E (MMAE; ADC) | Binds to CD30+ cells. After internalization, the toxin MMAE, disrupts microtubules and induces apoptosis | 2012/2011 | Seattle Genetics | (156–161) |
| Acute myeloid leukemia | CD33 | Gemtuzumab ozogamicin | Mylotarg | Humanized IgG4 linked to N-acetyl gamma calicheamicin (ADC) | Binds to CD33+ cells. After internalization, the toxin induces double-stranded DNA breaks and apoptosis. Does not activate ADCC | In review/in review; 2000* | Wyeth | (162–165) |
| Multiple myeloma   | CD38 | Daratumumab | Darzalex | Human IgG1 | Binds to CD38+ cells. Activates CDC, ADCC, and ADCP | 2016/2015 | Janssen Biotech | (166–170) |
| Multiple myeloma   | SLAMF7 | Elotuzumab | Empliciti | Humanized IgG1 | Binds to SLAMF7. Activates ADCC | 2016/2015 | Bristol-Myers Squibb | (171–176) |
| CLL                 | CD52 | Alemtuzumab | Campath | Humanized IgG1 | Binds to CD52+ lymphocytes. Activates ADCC and CDC | 2001/2001 | Genzyme | (177–179) |

*Adapted from Janice M. Reichert, PhD, The Antibody Society; last update July, 2017.
ADC, antibody–drug conjugate; ADCC, antibody–dependent cell-mediated cytotoxicity; ADCR, antibody–dependent cellular phagocytosis; ALL, acute lymphoblastic leukemia; CDC, complement-dependent cytotoxicity; CLL, chronic lymphoblastic leukemia; MAE, monomethyl auristatin E; NHL, non-Hodgkin lymphoma; scFv, single-chain variable fragment.
Withdrawn or marketing discontinued for the first approved indication.
NA, not approved or in review in the EU, not approved or information on review status not available in the US.
Color shades corresponds to structurally related target molecules.
| Antibody target | Nature of the target | Function | Expression | Monoclonal antibody effects in cancer therapy | Reference |
|-----------------|----------------------|----------|------------|---------------------------------------------|-----------|
| PDGFβα          | Protein of the tyrosine kinase family | Cell proliferation, differentiation and migration | Ubiquitous, highly expressed on endothelial cells | Cell proliferation inhibition (180, 181) |           |
| HER2            | Glycoprotein of the tyrosine kinase family | Enhances cell proliferation and favors survival | Epithelial cells, highly expressed on many tumors | Cell proliferation inhibition (182, 183) |           |
| EGFR            | Glycoprotein of the tyrosine kinase family | Cell proliferation and differentiation in cancer | Epithelial cells | Cell proliferation inhibition (184, 185) |           |
| VEGFA           | Glycoprotein of the PDGF/VEGF family | Proliferation and migration of endothelial cells | Hypoxic cells, highly expressed on many tumors | Angiogenesis inhibition (186, 187) |           |
| VEGFR2          | Cell surface receptor of the tyrosine kinase family | Proliferation and migration of endothelial cells | Vascular and lymphatic endothelial cells | Angiogenesis inhibition (186, 187) |           |
| PD-L1           | Protein of the immunoglobulin superfamily | Inhibits T cell activation and cytokine production | Myeloid and lymphoid lineage cells, highly expressed on certain cancer cells | Immune checkpoint inhibition (188, 189) |           |
| PD-1            | Protein of the immunoglobulin superfamily | Inhibits T cell activation and cytokine production | B and T lymphocytes | Immune checkpoint inhibition (188, 189) |           |
| CTLA-4          | Protein of the immunoglobulin superfamily | Inhibits T cell activation and cytokine production | B and T lymphocytes | Immune checkpoint inhibition (188–193) |           |
| RANK-L          | Ligand of the tumor necrosis factor superfamily | Activates osteoclast through NF-kappa B activation | Osteoblasts and T lymphocytes | Inhibition of bone destruction (191–193) |           |
| IL-1α           | Cytokine of the interleukin-1 family | Pleiotropic effects, including inflammatory response and apoptosis | Secreted by activated macrophages and monocytes | Cell growth inhibition and anti-inflammatory (194) |           |
| GD2             | Cell surface glycolipid receptor | Attachment of tumor cells to extracellular matrix | Nervous system cells and melanocytes, highly expressed on neuroblastomas and melanomas | Activates CDC and ADCC (195, 196) |           |
| EpCAM           | Cell surface glycoprotein | Cell adhesion | Epithelial tissues, highly expressed on carcinomas | Activates CDC, ADCC, and ADCP (188, 189, 197, 198) |           |
| CD3             | Cell surface glycoprotein of the immunoglobulin superfamily | T cell receptor signal transduction | T lymphocytes | Activates CDC and ADCC (188, 189) |           |
| CD19            | Surface antigen of the immunoglobulin superfamily | B cell differentiation and activation | B lymphocytes and DC | Activates CDC and ADCC (188, 189) |           |
| CD20            | Surface antigen of the MS4A family | B cell development and activation | B lymphocytes and a subset of T cells | Activates CDC, ADCC, and ADCP (188, 189) |           |
| CD22            | Surface antigen of the immunoglobulin superfamily | B cell signaling and adhesion | B lymphocytes | ADC (188, 189) |           |
| CD30            | Cell surface antigen of the TNF receptor superfamily | Pleiotropic effects, including lymph proliferation, differentiation, and activation | T and B lymphocytes and natural killer (NK) cells | ADC (188, 189) |           |
| CD33            | Cell surface lectin | Cell adhesion and apoptosis | Myeloid lineage cells | ADC (188, 189) |           |

(Continued)
| Antibody target | Reference | Monoclonal antibody effects in cancer therapy | Nature of the target | Function expression |
|----------------|-----------|--------------------------------------------|---------------------|--------------------|
| CD38 ADP-ribosyl cyclase 1 | (188, 189) | Activates CDC, ADCC, and ADCP | Cell surface glycoprotein | Cell activation and adhesion NK cells, DC, and macrophages, high-activated T cells |
| SLAMF7 Signaling lymphocytic activation molecule family member 7 | (188, 189) | Activates CDC and ADCC | Cell surface receptor of the CS2 family | NK cells activation T and B lymphocytes, NK cells, DC, and monocytes |
| CD52 CAMPATH-1 | (188, 189) | Activates CDC and ADCC | Cell surface glycoprotein | Modulates lymphocytes activation and adhesion T and B lymphocytes, NK cells, NK cells, monocytes, macrophages, and sperm cells |

**ADC, antibody–drug conjugate; ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; CDC, complement-dependent cytotoxicity; DC, dendritic cells; MS4A, membrane-spanning 4-domains subfamily A; NK cells, natural killer cells.**

Color shades correspond to structurally related target molecules.

**Table 3**

Corraliza-Gorjón et al. Combinations Using Therapeutic Antibodies for Cancer Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1804

Antibodies, not yet approved, but mentioned on this review are summarized on **Table 4**.

From the antibodies approved (or under review) for the treatment of solid tumors, seven of them recognize tumor cell surface tyrosine kinase receptors involved in proliferation and survival pathways. These receptors (see **Table 3**) are PDGFRα (targeted by the antibody olaratumab), HER2 (pertuzumab, trastuzumab and emtansine, ado-trastuzumab) and epidermal growth factor receptor (EGFR, necitumumab, panitumumab, and cetuximab). Two antibodies inhibit tumor angiogenesis by binding to the soluble ligand VEGF (bevacizumab) or to the endothelial cell receptor VEGFR2 (ramucirumab). Six of the mAb disrupt inhibitory immune checkpoint signals by binding to the programmed cell death protein 1 (PD-1) receptor on the T cells (nivolumab and pembrolizumab), to PD-L1 on the tumor cells (atezolizumab, durvalumab, and avelumab) or to CTLA-4 on T cells (ipilimumab). Two of these mAb block the binding of cytokines that are involved in the growth of some tumors, including antibodies against RANK-L (denosumab) and IL-1α (MABp1). The last three mAb recognize antigens overexpressed on the surface of tumor cells. They identify GD2 (dinutuximab) and EpCAM (edrecolomab and catumaxomab) (**Table 1**).

From the antibodies approved (or under review) for the treatment of hematopoietic neoplasias, eight antibodies recognize B cell antigens. Among those, one recognizes CD19 (blinatumomab), five mAb recognize CD20 (obinutuzumab, ofatumumab, rituximab, ibritumomab tiuxetan, and 131I tositumomab), one mAb binds to CD22 (inotuzumab ozogamicin), and the last one recognizes CD52 (alemtuzumab). Other two antibodies identify antigens expressed by B cells and by other cells of the immune system, including an anti-CD30 mAb (shared between B and T cells, brentuximab vedotin) and an anti-SLAMF7 (present on activated B cells and natural killer (NK) cells among others, elotuzumab). In addition, there are two antibodies against other immune cells, an anti-CD33 (myeloid lineage, gemtuzumab ozogamicin); and the non-lineage-restricted CD38 (daratumumab) (**Table 2**).

We will describe in the following paragraphs a set of clinical trials using antibodies in combination for oncological treatments, giving a systematic description of the antibody combinations with biological agents and their rationale. Describing the current aims of antibody-mediated cancer therapy and to envisage where its future lies. In addition, there will be a section where the therapeutic effects and toxicities for selected clinical trials will be discussed, which will help us to envisage the future of therapeutic antibodies for cancer treatments. Before starting with this systematic analysis, we will describe, with one example, in this case for the treatment of GD2⁺-neuroblastomas, the complexity of the clinical trials being carried out.

**EVALUATION OF TREATMENT COMPLEXITY WITH ANTIBODY IN COMBINATIONS**

In this section, we will discuss, as an example, the use of anti GD2 antibodies for the treatment of GD2-positive solid tumors, including neuroblastoma (266–269). Near 50 clinical assays have
# Table 4

| Antibody name | Molecular format | Company or Institute | Target/main characteristics | Reference/Clinical Trial identifier |
|---------------|------------------|---------------------|----------------------------|-------------------------------------|
| 3H1 (CEA-Vac) Mouse IgG1 | Titan Pharmaceuticals | Anti-idiotypic antibody that mimics an epitope of the carcinoembryonic antigen (CEA) | (199)/NCT00033748 |
| 5B1 (MVT-5873) Human IgG1 | MabVax Therapeutics | Carbohydrate determinant 19-9 (CA19-9, carbohydrate antigen sialyl-Lewis A) | (200)/NCT03118349 |
| 11D10 (TriAb) Mouse IgG1 | Titan Pharmaceuticals | Anti-idiotypic antibody that mimics a human milk fat globule membrane epitope | (201)/NCT00033748, NCT0045617 |
| A27.15 Mouse IgG1 | University of Arizona | Anti-transferrin receptor (TfR) antibody that blocks the binding of transferrin | (202)/NCT0003082 |
| Abagovomab Mouse IgG1 | CellControl Biomedical Laboratories; Menarini | Anti-idiotypic antibody that mimics an epitope of the ovarian cancer tumor-associated antigen CA-125 | (203)/NCT0058435, NCT01959672 |
| Andecaliximab (GS-5745) Humanized IgG4 | Gilead Sciences | Anti-matrix metalloproteinase 9 antibody that inhibits its enzymatic activity | (204, 205)/NCT02864381 |
| B-701 Human IgG1 | BioClin Therapeutics | Fibroblast growth factor receptor 3. Antagonist | (206)/NCT03123055 |
| Basiliximab (Simulect) Chimeric mouse–human IgG1 | Novartis; Cerimon Pharmaceuticals | Interleukin-2 receptor alpha-subunit (IL-2Ra, IL2Ra, CD25). Antagonist | (207)/NCT00626483 |
| BMS-986179 Bristol-Myers Squibb | Bristol-Myers Squibb | Mesothelin (MSLN). Antibody conjugated to an undisclosed cytotoxic drug | (208)/NCT02341625 |
| BTH1704 Humanized IgG1 | Cancer Research UK; Eliothera | Ecto-5'-nucleotidase (CD73) | (209–211)/NCT02754141 |
| Cabiralizumab (FPA008) Humanized IgG4 | Five Prime Therapeutics; Bristol-Myers Squibb; Ono Pharmaceutical | Mucin-1 (MUC1). Antibody | (212)/NCT02132403 |
| Canakinumab (ACZ885) Fully human IgG1 | Novartis Pharmaceuticals | Colony-stimulating factor 1 receptor (CSF1R). Antagonist | (213)/NCT02526017, NCT03158272 |
| Carotuximab (TRC105) Chimeric mouse-human IgG1 | Roswell Park Cancer Institute; Santen Pharmaceutical; TRACON Pharmaceuticals | Interleukin-1 beta (IL-1beta, IL-1b). Antagonist | (214)/NCT02900664 |
| CJM112 Fully human IgG1 | Novartis | Leukocyte surface antigen CD47. Antagonist | (215)/NCT03181308 |
| CC-90002 Humanized IgG | Inhibrix; Celgene Corporation | Endoglin (CD105). Inhibitor | (216)/NCT02367196 |
| CDX-1401 Human antibody fusion protein | Ludwig Institute for Cancer Research; Celldex Therapeutics Inc | Dendritic and epithelial cell receptor DEC205. Antibody linked to the tumor-associated antigen NY-ESO-1 | (217)/NCT02129075, NCT02495636 |
| Cergutuzumab amunaleukin (CEA-IL2v, RG7813) Immunocytokine | Roche | CEA. Antibody fused to a single IL-2 variant moiety with abolished CD25 binding | (218)/NCT02350673 |
| Conatumumab (AMG 655) Fully human IgG1 | Amgen; Takeda | Interleukin-17A (IL-17, IL-17A). Antagonist | (219)/NCT03111992, NCT02900664 |
| Darleukin (L19-IL2) Immunocytokine, fusion protein | Philogen; Bayer Healthcare Pharmaceuticals | Tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2, DR5). Agonist | (220)/NCT01327612 |
| Demcizumab (OMP-21M18) Humanized IgG2 | OncoMed Pharmaceuticals | Delta-like ligand 4 (DLL4). antagonist | (222)/NCT02722954 |
| Drozlitumab (PRO95780) Fully human, IgG1 | Genentech | TRAIL-R2 (DR5). Agonist | (223)/NCT00851136 |

(Continued)
| Antibody name       | Molecular format | Company or Institute                  | Target/main characteristics                                                                 | Reference/Clinical Trial identifier |
|---------------------|------------------|--------------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------|
| E2.3                | Mouse IgG1       | Salk Institute                       | Anti-TfR antibody that blocks the binding of transferrin to the receptor                       | (202, 224)/NCT000003082            |
| Emactuzumab (ROS509554) | Humanized IgG1  | Roche                               | CSF1R (CD115). Antagonist                                                                     | (225)/NCT02760797                  |
| EMD 525797 (O17E6)  | Humanized IgG2   | EMD Serono; Merck Serono             | Integrin alpha-V subunit (CD51). Antagonist                                                   | (226)/NCT01098475                  |
| Embetuzumab (LY2875358) | Humanized IgG4  | Eli Lilly                           | c-Met receptor tyrosine kinase (c-MET; MET; hepatocyte growth factor receptor; c-Met proto-oncogene) | (227)/NCT02082210                  |
| Epratuzumab (AMG 412) | Humanized IgG1  | Immunomedics                        | Anti-CD22 antibody that mediates antibody-dependent cellular cytotoxicity (ADCC)             | (228)/NCT00941928                  |
| Ficlatuzumab (AV-299, SCH 900106) | Human IgG1       | AVEO Pharmaceuticals                 | Hepatocyte growth factor (HGF). Inhibitor                                                    | (229)/NCT02277197                  |
| Ganitumab (AMG 479) | Fully human IgG1 | Amgen; NantWorks; Takeda            | Insulin-like growth factor 1 receptor. Antagonant                                              | (230)/NCT00789857, NCT01327612     |
| GD2Bi-aATC (HuSFBBi-armed ATC) | Humanized bispecific | National Cancer Institute; Barbara Ann Karmanos Cancer Institute | CD3 and disialoganglioside GD2                                                                | (231, 232)/NCT02173093             |
| Imalumab (BAX69)    | Fully human      | Cytokine PharmaSciences; Shire      | Macrophage migration inhibitory factor. Inhibitor                                             | (233)/NCT02488810                  |
| IMC-CS4 (LY3022855) | Human IgG1       | ImClone Systems                     | CSF1R (C-FMS; CD115)                                                                        | (234)/NCT03153410                  |
| Intetumumab (CNTO 95) | Fully human IgG1 | Centocor; BeGene                   | Anti-Integrin alpha-V subunit (CD51) antibody that blocks both alpha-v beta-3 and alpha-v beta-5 integrins | (235)/NCT00880043                  |
| Linilumab           | Humanized monoclonal antibody (mAb) IgG4 | Bristol-Myers Squibb               | KIR (killer-cell immunoglobulin-like receptors)                                              | (236)/NCT01714739                  |
| M170                | Mouse IgG1       | University of California, Davis     | MUC1                                                                                         | (237)/NCT00009750                  |
| MEDI6617            | Human IgG1       | MedImmune                           | Angiopoietin 2. Antagonist                                                                   | (238)/NCT01248949, NCT02141542     |
| Milatuzumab (hLL1)  | Humanized IgG1   | Immunomedics                        | CD74                                                                                         | (239)/NCT00989586                  |
| Minivetuximab soravtansine (IMGN683) | Chimeric mouse-human, ADC | ImmunoGen                          | Folate receptor 1. Antibody conjugated to the maytansinoid DMA (N2′-Deacetyl-N2′-(4-mercaptop-4-methyl-1-oxopentyl)-maytansine) | (240)/NCT02806305                  |
| MM-111              | Human bspecific  | Merrimack Pharmaceuticals            | ErbB receptors ErbB2 and ErbB3. Inhibitor                                                    | (241)/NCT01097460                  |
| MNRF168SA           | Fully human IgG1 | Genentech; Roche                    | Neuropilin-1. Inhibitor                                                                    | (242)/NCT00954642                  |
| MOX0916             | Humanized IgG1   | Genentech                           | OX40. Antagonist                                                                            | (243)/NCT02410512                  |
| Navicizumab (OMP-305B83) | Bispecific Humanized IgG2 | OncoMed Pharmaceuticals          | Delta-like Igand 4 (DLL4) and vascular endothelial growth factor A (VEGF). Inhibitor         | (244)/NCT03030287, NCT022983857    |
| Nimotuzumab (TheraCim hR3, BIOMab EGFR, Theraloc) | Humanized IgG1 | Center of Molecular Immunology; CimYM | Epidermal growth factor receptor (EGFR). Inhibitor                                            | (245)/NCT02947386                  |
| Offertuzumab (TRU-016) | Recombinant single-chain polypeptide | Aptevo Therapeutics            | CD37                                                                                         | (246)/NCT01317901                  |
| Parsatumab (MEG0444A) | Humanized IgG1 | Genentech                           | Potential immunostimulatory and antineoplastic activities                                      | (247)/NCT01399684                  |
| PD-0360324          | Humanized IgG2   | Pfizer                              | Cytokine CSF1 (CSF-1, macrophage colony-stimulating factor, M-CSF). Inhibitor                | (248)/NCT02554812                  |

(Continued)
| Antibody name               | Molecular format | Company or Institute                  | Target/main characteristics                                                                                                                                                                                                 | Reference/Clinical Trial identifier |
|----------------------------|------------------|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| PDR001                     | Humanized IgG4   | Novartis                              | Programmed cell death protein 1 (PD-1), Inhibitor                                                                                                                                                                            | (13)/NCT02900664, NCT03111992     |
| PF-04518600                | Fully human IgG2 | Pfizer                                | OX40, Agonist                                                                                                                                                                                                                  | (249)/NCT02554812                 |
| Pidilizumab (CT-011, MDV9300) | Humanized IgG1  | CureTech; Medivation                  | PD-1, Inhibitor                                                                                                                                                                                                                | (250)/NCT01067287                 |
| Relatlimab BMS-986016     | Human mAb IgG4   | Bristol-Myers squib                    | LA9-3 (human lymphocyte activation gene 3 protein), Potential immune checkpoint inhibitory and antineoplastic activities                                                                                                      | (251)/NCT01968109, NCT02061761    |
| Rilotumumab (AMG102)      | Fully human IgG2 | Amgen                                 | Human hepatocyte growth factor (HGF, c-Met), Inhibitor                                                                                                                                                                          | (252)/NCT00788957                 |
| R069586688                 | Bispecific       | Roche                                 | CD3 and CEA, Inhibitor                                                                                                                                                                                                          | (253, 254)/NCT02650713            |
| RO7009789 (CP-870,893)    | Fully human IgG2 | Roche                                 | CD40, Agonist                                                                                                                                                                                                                  | (255)/NCT02665416, NCT02760797   |
| Rovalpituzumab tesirine (SC16I6D6.5) | Humanized ADC | StemcentRx                           | Delta-like protein 3 (DLL3), Antibody conjugated to tesirine, a pyrrolobenzodiazepine dimer                                                                                                                                     | (256)/NCT03026166                 |
| SGN-LIV1A                  | Humanized ADC    | Seattle Genetics                      | Zinc transporter LIV-1 (SLC39A6), Antibody conjugated to maleimidoacyclovaline-citrulline-p-aromaticbenzyloxycarbonyl-MMAE (vcMMAE)                                                                                                  | (257)/NCT01969643                 |
| SS1 (dsFv) PE38 (CAT-5001) | Immunotoxin      | National Institutes of Health (USA)   | MSLN, Single-chain antibody linked to Pseudomonas exotoxin PE-38                                                                                                                                                            | (258)/NCT01051934                 |
| Tigatuzumab (CS-1008)     | Humanized IgG1   | Daiichi Sankyo Company; University of Alabama at Birmingham | TRAIL-R2 (DR5). Agonist, TRAIL-R2 (DR5), Agonist                                                                                                                                                                           | (259, 260)/NCT01307891           |
| Urelumab (BMS-663513)     | Fully human IgG4 mAb | Bristol-Myers Squib              | Anti-CD137, Potential immunostimulatory and antineoplastic activities                                                                                                                                                             | (261)/NCT01471210, NCT01775631, NCT02110082, NCT02253992 |
| Uutomilumab (PF-05082566) | Human IgG2       | Pfizer                               | CD137 (4-1BB), Agonist                                                                                                                                                                                                          | (262)/NCT02554812                 |
| Vanucizumab (RG7221)      | Bispecific       | Roche                                 | Angiopoietin 2 (ANG2, ANGPT2) and vascular endothelial growth factor (VEGF), Inhibitor                                                                                                                                          | (263)/NCT01688206, NCT02665416, NCT02715531 |
| Varilumab (CDX-1127)      | Fully human IgG1 | Celldex Therapeutics                  | CD27, Agonistic                                                                                                                                                                                                                 | (16)/NCT02410612                  |
| Veltuzumab (IMMU-106, hA20) | Humanized        | Immunomedics                          | Anti-CD20 antibody that triggers complement-dependent cell lysis and antibody-dependent cell-mediated cytotoxicity (ADCC)                                                                                                      | (264)/NCT00989586                 |
| VGX-100                   | Fully human IgG1 | Circadian Technologies Limited        | Vascular endothelial growth factor C (VEGF-C or Flt4 ligand), Inhibitor                                                                                                                                                        | (265)/NCT01514123                 |

*Only clinical trials included in this review.*
been started using two different mouse antibodies and their corresponding chimeras or humanized antibodies. The clinical use of dinutuximab (ch14.18) was approved in 2015, whereas the therapeutic efficacy of the other antibody, 3F8 has been demonstrated with many patients (270–272). These antibodies, recognizing the neuroblastoma tumor-associated antigen GD2, are being used to (i) kill the tumor with either the naked antibody alone, apparently through Fc-mediated effector actions [antibody-dependent cell cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell phagocytosis (ADCP)] or apoptosis (NCT00002458, NCT0072358, NCT01418495, NCT01419834, NCT01704872, NCT02258815, NCT02743429); (ii) kill the tumor by the naked antibody in combination with chemotherapeutic agents (busulfan, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, lomustine, melphalan, or vincristine), small molecule drugs (crizotinib), external radiation, and/or conventional surgery (NCT03098030, NCT03126916); (iii) directly transport a radionuclide toward the tumor, by conjugating the radionuclide to the anti-GD2 mAb. This will induce radiolysis of the tumor cells, minimizing the effects on normal cells (NCT00058370, NCT00445965, NCT03126916); (iv) use them in combination with agents that modify cell expression patterns, inhibiting proliferation and inducing cell differentiation and apoptosis [i.e., isotretinoin (13-cis retinoic acid or RA) (NCT00053022, NCT0030719, NCT01183416, NCT01183429, NCT01183884, NCT01526603, NCT01711554, NCT02100930, NCT03033303); or (v) use them in combination with agents able to burst the host immune response against the tumor. These include, granulocyte-macrophage colony-stimulating factor (GM-CSF) or granulocyte colony-stimulating factor (G-CSF) (NCT01704756, NCT01767194, NCT02484443, NCT02502786, NCT03189706); which increase the number of innate immune response cells by triggering the proliferation of granulocytes and macrophages; increasing both innate and adaptive responses by inducing the maturation/proliferation of NK cells and T lymphocyte proliferation with interleukin-2 (IL-2) alone or in combination with GM-CSF and/or RA (NCT0005576, NCT0026312, NCT01041638, NCT01592045, NCT01662804, NCT02169609, NCT02641782); regulating the threshold of the immune response with an adjuvant, changing the secreted cytokine expression pattern of cells bearing certain pattern recognition receptors (i.e., beta glucan that binds the C-type lectin receptor Dectin-1) (NCT00037011, NCT00492167, NCT00089258); increasing the pool of cytotoxic cells able to fight the tumor with allogeneic NK cells (NCT00877110, NCT1857934, NCT2573896, NCT2650648); using in vitro activated T cells coated with bispecific OKT3-hu3F8 mAb, together with IL-2 and GM-CSF to redirect T lymphocyte cell lysis (NCT02173093); and combining the anti-GD2 antibody with nivolumab, an anti-immune check-point (PD-1) mAb able to block the immunosuppressor activity induced by the tumor (NCT02914405).

From these “basic” aims further combinations arose, for example one where the aim is to induce radiolysis of the tumor cells with 111I-3F8, simultaneously bursteing the innate immune response with filgastrim (G-CSF), inhibiting neo-vascularization with bevacizumab (anti-VEGF), together with autologous stem cell rescue of irradiated patients (NCT00450827).

We believe that this example gave a rough idea of the complexity that clinical trials for one antibody (two in this case) can reach. The chimeric, human-murine, anti-GD2 mAb dinutuximab has been approved in combination with GM-CSF, IL-2, and retinoic acid for the treatment of pediatric patients with high-risk neuroblastoma (273). Interestingly, the overall survival and event-free survival of patients treated with dinutuximab increased 2 years when compared to standard treatment during phase III clinical trials (273).

**COMBINATION OF ANTIBODIES WITH NON-BIOLICALGICAL AGENTS**

Chemotherapeutic drugs are cytotoxic agents affecting unspecifically cell proliferation and survival, which inhibit topoisomerases I or II (doxorubicin, etoposide, irinotecan, topotecan, etc.), produce DNA breaks interfering with DNA replication, RNA transcription and cell division through changes in DNA alkylation, DNA methylation, and DNA cross-linking or intercalating between base pairs in the DNA helix (busulfan, melphalan, cyclophosphamide, carboplatin, cisplatin, lomustine, thiopeta, etc.). These chemotherapeutic drugs are being used in combination with mAbs for many cancer treatments (274).

In addition to surgery, treatment with antibodies and external irradiation has also been used. Localized external irradiation allows, by destroying tumor cells, better exposure of the tumor antigens to the immune system cells, this combination is also working well and is being used in numerous clinical trials (275–279).

Small molecule drugs that inhibit molecular interactions or enzymatic activity of proteins involved in cell signaling, or inhibitors of protein kinases overexpressed in tumor cells (including erlotinib, ibrutinib, imatinib, lapatinib, olaparib, regorafenib, ruxolitinib, sorafenib, sunitinib, etc.), are also being used in combination with antibodies (280, 281). There are numerous examples of treatments with this type of combinations that, by simultaneously inhibiting ligand–receptor interactions and kinases belonging to the same signaling pathway, have led to very positive therapeutic results (282–286).

**COMBINATION OF ANTIBODIES WITH BIOLOGICAL AGENTS**

These are therapies that use a combination of antibodies or antibody-based molecules with other biological substances, for example, recombinant proteins, genetic material, virus, bacteria, and cells (16). Most of these strategies are designed to stimulate the host immune system to act against the cancer cells.

In the following paragraphs, we describe antibodies in combinations, where (i) one of the antibodies identifies a tumor-associated antigen (an antigen overexpressed in tumor cells), used either naked, as an antibody–drug conjugate (ADC) or as an immunotoxin; (ii) antibodies against the tumor cell are used in combination with cytokines or immunocytokines to burst the immune response against the tumor, or conversely use anti-cytokine antibodies when the expressed cytokines can be
harmful for the antitumor response, aiming to disrupt their balance; (iii) the antibodies directly target the angiogenesis process, aiming to inhibit new vascularization required for tumor growth; (iv) the mAb can also be combined with effector cells to increase the immune response against the tumor; or (v) combined with antibodies against immunomodulatory or immunostimulatory proteins to disrupt the inhibitory signals sent by the tumor to the host immune system to inhibit the antitumor response. Although several of the examples we will describe could be included more than one sub-heading, each one of them is described only in one of them.

**Antibodies Against Tumor-Associated Antigens**

The rationale of using antibodies as therapeutic agents was to kill the tumor cells either directly or through activating the patient's immune system effector functions (ADCC, CDC, or phagocytosis) with antibodies specific for tumor-associated antigens. Mucin 1 (MUC-1), an antigen present on the surface of many adenocarcinomas, which is recognized by mAb m170 (237). This mAb has been used radiolabeled as $^{111}$In-m170 or $^{90}$Y-m170, in combination with chemotherapy and the immunosuppressor cyclosporine to treat patients with metastatic prostate cancer that did not respond to hormone therapy. This treatment was followed by peripheral stem cell transplantation (NCT00009750). The rationale is to kill the tumor with the combination of chemotherapy and the mAb coupled to the radioisotope in the presence of cyclosporine. Afterward peripheral stem cell transplantation will allow to refurbish the hematopoietic compartment.

Other approaches have been used on hematological neoplasias, one of them, a combination of two anti-transferrin receptor (TfR) antibodies A27.15 and E2.3 (202, 287) was used for the treatment of chronic myeloproliferative disorders (NCT00003082). The anti-TfR mAb block the binding of (Fe$^{3+}$)2-transferrin to TfR, resulting in decreased tumor cell growth. Other targets used in hematopoietic malignancies are CD20 and CD74. In this case, a combination of the anti-CD20 mAb veltuzumab (IMMU-106) (288) and milatuzumab (anti-CD74) (239) was used to treat relapsed or refractory B cell non-Hodgkin lymphoma (NCT00989586). CD74, a surface receptor of the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF) (289–291), is an MHC class II chaperone and an accessory-signaling molecule (292). Milatuzumab induces apoptosis, related to inhibition of CD74 activation by MIF, ADCC, or CDC (293), while veltuzumab triggers CDC and ADCC in cells that overexpress CD20 (288). Other combinations include rituximab (anti-CD20) in combination with CC-90002 (anti-CD47) (294, 295) for the treatment of advanced solid and hematologic cancers (NCT02367196). CC-90002 selectively binds to CD47 expressed on tumor cells, blocks CD47 interaction with signal regulatory protein alpha (SIRPα), a protein expressed on phagocytic cells, which prevents CD47/SIRPα-mediated signaling and abrogates the CD47/SIRPα-mediated inhibition of phagocytosis. The result is an induction of pro-phagocytic signaling, resulting in macrophage activation and the specific phagocytosis of tumor cells. In addition, CD47 signaling blockade activates both, an antitumor T lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47 and its interaction with SIRPα leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, resulting in cancer cell proliferation (294, 296–298).

**ADC and Immunotoxins**

Some antitumor treatments use, rather than naked antibodies, antibody–toxin fusion proteins (immunotoxins) or antibodies linked to drugs (299–302). In some cases, to increase the cell-killing potential of antibodies, they can be covalently linked to potent cytotoxic or cytostatic agents, including small molecule drugs or inactive forms of a biological toxin. The antibody directs the toxin toward the tumor cell. When the cell endocytoses the ADC, it undergoes enzymatic cleavage and the drug is released, gets activated, and exerts its cytotoxic action, killing the tumor cell. The endocytic process works for antigens that can be internalized. Most of the current antibodies that are being used as ADC identify cell surface receptors that are efficiently endocytosed. However, many cell surface proteins are not internalized and a large amount of work is being carried out to develop alternatives, such as making an ADC where the antibody is coupled to the drug through a linker that can be cleaved by tumor cell-surface proteases, when in close contact with the tumor cell; conversely the antibody may carry a tumor receptor antagonist to direct it toward the tumor cell surface (303, 304).

One example includes a combination of an antitumor-associated antigen mAb and an ADC. Trastuzumab in combination with an antibody against the zinc transporter LIV-1 (SLC39A6) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) (257) for the treatment of patients with metastatic breast cancer (NCT01969643). In this particular combination, trastuzumab inhibits the tyr-kinase receptor HER2, while through the potent microtubule disrupting agent MMAE, which is coupled to the anti-LIV-1 antibody, induces cell cycle arrest in the G2/M phase and apoptosis of LIV-1$^+$ cells (257). This type of combination can be made more potent by adding to the equation, antibodies against immune-checkpoints to burst antitumor immune responses. For example, the combination of nivolumab, ipilimumab, and rovalpituzumab tesirine has been used in extensive-stage small cell lung cancer (SCLC) (NCT03026166). Rovalpituzumab tesirine is an anti-delta-like protein 3 (DLL3) antibody conjugated to the cytotoxic pyrrolobenzodiazepine dimer D6.5 (256, 305). This antibody recognizes the membrane protein DLL3, which is overexpressed in certain tumors, binds to Notch receptors, and regulates Notch-mediated signaling (256). Thus, this combination should kill the cells overexpressing DLL3, while the anti-checkpoint antibodies nivolumab and ipilimumab redirect the host immune response to attack the tumor.

Another example shows the combination of mAb CR011, against the transmembrane protein GPNMB (glycoprotein non-metastatic B) coupled to MMAE (306). This ADC was used in combination with anti-PD-1 mAb nivolumab or pembrolizumab and varilumab (307, 308), an agonistic anti-CD27 mAb, for the treatment of advanced melanoma (NCT02302339). The rationale
is, in addition to targeting the GPNMB+ cells with the antibody-coupled to the toxin, the anti-PD-1 antibodies suppress the tumor-promoted inhibition of the antitumor immune response, while the anti-CD27 triggers an activation of the cytotoxic T lymphocytes (CTL).

The following example combines the ADC mirvetuximab soravtansine with either bevacizumab (VEGF) or pembrolizumab (PD-1) in primary peritoneal, fallopian tube, or endometrial cancer (NCT02060305). Mirvetuximab soravtansine is an immunoconjugate consisting of a folate receptor 1 (FOLR1) mAb (M9346A) conjugated to the cytotoxic maytansinoid DM4 (240). DM4 is released after internalization, binds to tubulin, and disrupts microtubule dynamics. FOLR1 is a member of the folate receptor family, overexpressed on a variety of epithelial-derived cancer cells (240, 309). Other studies combine nivolumab (anti-PD-1) with the ADC BMS-986148 (208, 310), composed of a mAb against the cell surface glycoprotein mesothelin (MSLN), conjugated to an as of yet undisclosed cytotoxic drug, for the treatment of mesothelioma, NSCLC, ovarian cancer, pancreatic cancer, and gastric cancer (NCT02341625). The rationale here is to block with the anti-PD-1 mAb the binding of PD-L1 (present on the tumor cells) to its receptor PD-1 (present on T cells), avoiding the suppression of antitumor responses triggered by the PD-L1/PD-1 interaction, while targeting mesothelin+ cells with the BMS-986148 mAb. Since the mAb is an ADC, upon internalization the cytotoxic agent kills the tumor cells. The mAb also activates ADCC. Another combination, for the treatment of MSLN-expressing NSCLC uses a combination of the anti-VEGF antibody bevacizumab with the single-chain anti-MSLN mAb SS1 (dsFv) linked to the exotoxin PE-38 from Pseudomonas (258) (NCT01051934). Since MSLN is not shed in significant amounts into the bloodstream, the dsFv-toxin can be concentrated onto the tumor cell surface. Once the dsFv toxin is internalized, the toxin is released and inactivates eukaryotic translation elongation factor 2, disrupting tumor cell protein synthesis. Concomitantly, the anti-VEGF antibody inhibits angiogenesis (258).

**Antibodies Combined with Cytokines and Immunocytokines**

Another way to burst the host immune response against the tumor involves the use of either exogenous cytokines or fusion proteins that include a cytokine, administered either systemically or directly in the tumor. In some cases, due to cytokine toxicity, it could be envisaged to directly couple the cytokine to a mAb specific for a tumor-associated antigen, as a recombinant fusion protein (311, 312). These combinations allow, decreasing the dose, to reach higher local concentrations at the tumor site and to exert its therapeutic function avoiding systemic toxicity, while increasing the cytokine’s half-life, since it is coupled to the antibody, which prevents renal clearance (313).

In another example for the treatment of advanced or metastatic solid tumors, a combination of nivolumab and the Aldesleukin Prodrug NKTR-214 was used (NCT02983045). NKTR-214 is a recombinant human IL-2 conjugated to six releasable polyethylene glycol chains (PEG) (314). When the cytokine is released, binds to CD122 (IL-2 receptor beta subunit) and the mAb may act synergistically with NKTR-214 by blocking PD-1 activation through the mAb and simultaneously stimulating growth and cytotoxic activity against the tumor of the patient's T and NK cells by the exogenous IL-2. The advantages of using this conjugated form of the IL-2 are that, on the one side, is released in a controlled way in the tumor's proximity, avoiding systemic toxic effects; and on the other side, PEG conjugation prevents IL-2 binding to the IL2Ralpha subunit (and the subsequent activation of CD4-positive regulatory immunosuppressive T cells), while IL2Beta activation plays a key role on the proliferation and activation of effector T cells (314). In another clinical trial, the NKTR-214 immunocytokine was also administered, using a similar therapeutic strategy for the treatment of patients with metastatic urothelial bladder cancer or metastatic NSCLC, in combination with atezolizumab (74–76) (NCT03138889). Another trial for advanced or metastatic solid tumors expressing the carcinoembryonic antigen (CEA), combined atezolizumab and cergutuzumab amunaleukin [CEA-IL2 variant (IL2v)] (218), alone or together with a pretreatment with the anti-CD20 mAb obinutuzumab (NCT02350673). The immunocytokine CEA-IL2v is a fusion protein between a recombinant IL2v, unable to bind CD25, fused to the C-terminus of a high affinity, bivalent CEA-specific antibody (218). The strategy is to inhibit the PD-1/PD-1L checkpoint, increasing locally IL-2 activity on the tumor cells, allowing its binding to CD122. A similar strategy uses nivolumab in combination with the superagonist ALT-803 for the treatment of advanced and unresectable NSCLC (NCT02523469). ALT-803 is a fusion protein containing a mutated IL-15 (IL-15N72D) cytokine and a soluble, dimeric IL-15 receptor alpha Fc fusion protein (IL-15Ra-Fc) (315). The rationale of this study is to suppress the signaling through negative checkpoints, while activating and increasing NK levels and memory CD8+ T cells, through the binding of ALT-803 to the IL-2/IL-15 receptor beta gamma chain, strengthening the patient's immune response.

Another example is the anti-HER2 mAb trastuzumab, which has been used in combination with IL-12 in treating patients with recurrent solid tumors [breast cancer, endometrial carcinoma, gastric cancer, non-small cell lung cancer (NSCLC), SCLC, and ovarian epithelial cancer] (NCT00028535). IL-12 stimulates IFN-gamma production and enhances T- and NK-cell proliferation, differentiation, and activation (316). A more complex example combines two mAb-cytokine fusion proteins, consisting of L19, a human single-chain variable fragment directed against the extra-domain B (ED-B) of fibronectin, linked to either the human pro-inflammatory cytokine tumor necrosis factor alpha (TNFa, L19-TNF) or to human IL-2 (L19-IL2). These combinations have been used on patients with malignant melanoma (317–320) (NCT02076633). The rationale of the trial is that the L19 moiety binds to the ED-B domain of a fibronectin isoform selectively expressed in the tumor neovasculature during neo-angiogenesis. TNFa may locally induce an immune response against ED-B+ tumor cells, while the IL-2 moiety may locally activate CTL, NK cells, and macrophages.

In another clinical trial, atezolizumab was combined with (i) ipilimumab, (ii) interferon alfa-2b, (iii) PEG-interferon alfa-2a, (iv) bevacizumab and PEG-interferon alfa-2a, and (v) obinutuzumab, for the treatment of locally advanced or metastatic solid tumors (NCT02174172). The aim is to compare on the
same trial the results from these different strategies. The rationale is to restore the antitumor immune response by blocking immune checkpoints, while inducing cell cycle arrest, apoptosis or differentiation, which will lead to tumor growth inhibition, concomitant with T cell and NK cell activation, inhibition of angiogenesis and induction of cytokine expression, through the administration of interferon alpha (321).

**Anti-Cytokine Antibodies**

On the previous section, the aim was to provide exogenous cytokines to burst the antitumor immune response. Here, the aim is to disrupt the balance of other cytokines such as IL-17 or IL-1, that may hinder the antitumor immune response.

An example, for the treatment of patients with multiple myeloma, uses the anti PD-1 mAb PDR001 in combination with the mAb CJM112 (targeting IL-17) or with the Smac Mimetic LCL161 drug (an IAP inhibitor) (NCT03111992). This strategy aims to restore the cellular immune response inhibiting checkpoint signaling, changing the cytokine balance by decreasing the available IL-17 and favoring tumor cell apoptosis. A more complex clinical trial was used for the treatment of colorectal cancer, triple-negative breast cancer, NSCLC and adenocarcinoma, where the anti PD-1 mAb PDR001 (13) was used in combination with either (i) the anti-interleukin-1 beta (IL-1b) mAb canakinumab (214), (ii) the anti-IL-17 mAb CJM112 (219), (iii) the small molecule inhibitor trametinib (MAPKK1 and MAPKK2 inhibitor) or (iv) the EGFR antagonist nazartinib (NCT02900664). The aim is to inhibit the immune checkpoint, while either simultaneously suppressing the inflammatory responses (blocking IL-1b or IL-17), or inhibiting tumor cell proliferation with mitogen-activated protein kinase and EGFR inhibitors.

**Antibodies Targeting Angiogenesis**

Unlike to what happens with hematologic tumors, the growth of a solid tumor is concomitant with a local increase in nutrient and oxygen consumption and secretion of metabolites, requiring neo-vascularization for its growth. Therefore, some of the antitumor therapies aim to interfere with the neo-vascularization process, either by including antibodies against the soluble ligands, or against their receptors present in the cell surface of endothelial cells (322).

The anti-VEGF-A mAb bevacizumab, able to inhibit angiogenesis is currently being tested in combination with other therapeutic agents to determine its usefulness for cancer treatment. These combinations include: cetuximab, in advanced lung cancer (NCT00368892); MEDI3617 (anti-Ang-2) (238), for advanced solid malignancies (NCT01248949); the mAb drozitumab (PRO95780) (223) against death receptor 5 (DR5/TRAIL-R2), in metastatic colorectal cancer (NCT00851136); NK immunotherapy, in recurrent solid tumors (NCT02857920); and atezolizumab (NCT03038100, NCT02659384), nivolumab (NCT02873962), or pembrolizumab (NCT02853318) for the treatment of ovarian, fallopian tube, or primary peritoneal cancer. Bevacizumab has also been combined with MNRP1685A (242, 323), a mAb against membrane-bound endothelial cell co-receptor neuropilin-1 (NRPI), overexpressed in certain tumor cells, for advanced or metastatic solid tumors (NCT00954642). MNRP1685A prevents angiogenesis by blocking binding of VEGF, VEGF-B, and placental growth factor 2 to neuropilin-1, resulting in vessel immaturity. Other combinations of bevaci- zumab include parsatuzumab (247), a mAb against the vascular-restricted extracellular matrix protein epidermal growth factor-like domain multiple 7 (EGFL7), upregulated during angiogenesis and overexpressed on the cell surface of different solid tumors, for the treatment of metastatic colorectal cancer (NCT01399684). Parsatuzumab inhibits vascular development regulated by EGFL7, affecting to the survival and migration of endothelial cells during angiogenesis. An additional combination used bevacizumab and anti-VEGFC/Flt4 (VGX-100) (265) for metastatic solid tumors (NCT01514123). The rationale is to simultaneously inhibit vascular and lymphatic endothelial cell proliferation and angiogenesis.

A different approach is to target angiogenesis with the Anti-VEGFR-2 mAb ramucirumab, in combination with the anti-c-MET [hepatocyte growth factor receptor (HGFR)] mAb emibetuzumab (227), on advanced refractory solid tumors (NCT02082210). The rationale of the trial is to inhibit angiogenesis and MET signaling on the tumor cells (227). A similar strategy has been used where instead of using an anti-HGFR mAb, uses ficlatuzumab (229, 324), a mAb against the c-MET ligand (HGF), in combination with cetuximab (NCT02277197).

A similar strategy targets molecules with an expression highly restricted to the vascular endothelium. An example is the combination of pembrolizumab with demcizumab (222), a mAb that blocks the interaction of anti-delta-like ligand 4 (DLL4) with Notch-1 and Notch-4, inhibiting Notch-mediated signaling and gene transcription, impairing the productive growth of new blood vessels (325) (NCT02722954). Pembrolizumab avoids the immunosuppression by immune checkpoint signaling while demcizumab prevents angiogenesis.

In K-ras wild-type metastatic colorectal cancers, cetuximab mAb was used in combination with the alphaVbeta3 (vitronectin receptor) integrin inhibitor EMD 525797, an anti-alphaV integrin subunit mAb (226) (NCT01008475). AlphaVbeta3 integrin is a cell adhesion and signaling receptor expressed on the surface of tumor endothelial cells, with a crucial role in their adhesion and migration. The aim of the trial is to inhibit angiogenesis and endothelial cell interaction(s) with other cells or with the extracellular matrix, required for tumor angiogenesis and metastasis. A similar study in solid tumors combines bevacizumab with intetumumab (235, 326), a pan alpha-v human mAb that blocks both alpha-v beta-3 and alpha-v beta-5 integrins, resulting in inhibition of integrin-mediated tumor angiogenesis and tumor growth (NCT00888043).

The remaining clinical trials on this section, all of them combine an anti-checkpoint antibody (either anti-CTLA-4, PD-1 or PD-L1) with anti-angiogenic antibodies such as the anti-Angiopoietin 2 (Ang-2) mAb (MEDI3617) in metastatic melanoma (NCT02141542); with the antibody carotuximab (TRC105) (215) that recognizes the endothelial cell surface protein endoglin, essential for angiogenesis, in metastatic NSCLC (NCT03181308); with antibodies specific for Ang-1 and Ang-2, which prevent their interaction with their target tie2 receptors (NCT00861419); with vanucizumab (bispecific anti-VEGF/
Ang-2 antibody) (263), in advanced or metastatic solid tumors (NCT01688206). The bispecific mAb targets both VEGF-A and Ang-2, which are upregulated in a variety of tumor cell types, play key roles in tumor cell proliferation, angiogenesis and metastasis. The anti-VEGF-A arm is based on bevacizumab and the anti-Ang-2 arm is based on the anti-Ang-2 antibody LC06 (263). It simultaneously binds and neutralizes both VEGF-A and Ang-2. This prevents the activation of both VEGF-A/VEGFR- and Ang-2/Tie2-mediated signaling pathways, resulting in the inhibition of proliferation of VEGF-A- and/or Ang-2-overexpressing tumor cells (263, 327).

Another strategy is to combine the anti-EGFR mAb panitumumab with an anti-hepatocyte growth factor mAb alectinib (252) or ganitumab (230), an anti-insulin-like growth factor 1 receptor (IGF-1R) mAb in metastatic colorectal cancer with wild-type KRAS (NCT00788957) (328). The rationale here is to simultaneously inhibit strong proliferative signals triggered by EGFR and c-MET.

**Antibodies Combined with Effector Cells**

In some patients, the number of cells from the innate or adaptive immune system could be decreased by the effects of previous treatments. In these cases, treatments with antibodies, whose mechanisms of action depend on immune system cell effector functions (i.e., ADCC, ADCP, etc.), could be compromised. In these cases, either autologous (harvested prior to the treatment) or allogeneic cells (NK cells, T cells, CTL cells, dendritic cells (DC), etc.) can be administered concomitantly with the therapeutic antibodies.

A combination of mAb and cells for the treatment of hematological malignancies combines the anti-CD22 mAb epratuzumab (228) with haploidentical NK cells and low-dose exogenous IL-2, for the treatment of relapsed or refractory B lineage acute lymphoblastic leukemia (NCT02003222). The rationale is to target the CD20+ B cells, while putting in close contact T cells (CD3+) with CD19+ B cells, to mount a strong cytotoxic T cell response. The rest of the trials from this group, all of them combine mAb targeting immune-checkpoints (CTLA-4, PD-1, or PD-L1) with the bispecific antibodies. These include blinatumomab in relapsed or refractory precursor B-lymphoblastic leukemia (NCT02879695) or for relapsed or refractory B cell acute lymphoblastic leukemia (NCT03160079). The rationale for these trials is to avoid the suppression of antitumor responses, while putting in close contact T cells (CD3+) with CD19+ B cells.

Bispecific antibodies in combination have also been used for the treatment of solid tumors. For most of the examples, one of the arms of the bispecific mAb identifies a tumor-associated antigen, such as the bispecific antibody RO6958688 (bispecific CD3-CEA) combined with atezolizumab, for the treatment of advanced and metastatic solid tumors (NCT02650713). The bispecific antibody RO6958688 (253, 254) recognizes, on the one side, the CD3 molecule of the TCR and, on the other side, the CEA, an antigen overexpressed in several tumors. The rationale of the trial is to block the binding of PD-L1 to its receptor avoiding the suppression of antitumor responses, while putting in close contact T cells (CD3+) with the CEA+ tumor cells, inducing a strong T cell activation which may result in a potent antitumor CTL response. Similarly, solid tumors were treated with atezolizumab in combination with bevacizumab or with vanucizumab, a bispecific mAb that simultaneously targets VEGF and Ang-2 (NCT02715531). This treatment aims to block the immune checkpoint suppression while inhibiting angiogenesis.

Another example of targeting tumor-associated antigens is the use of in vitro-activated T cells armed with GD2Bi-aATC, a bispecific antibody that recognizes CD3 and GD2 (231, 232), in combination with IL-2 and GM-CSF in patients with neuroblastoma or osteosarcoma (NCT02173093). The rationale of this study is to generate in vitro activated T cells that are infused in the patient after binding to the bispecific mAb, which will direct them to the tumor, generating a potent CTL response to kill tumor cells. Exogenous IL-2 and GM-CSF are added to maintain these cells and generate an inflammatory environment surrounding the tumor. In addition, another approach that has been used is to combine the anti-HER2 antibody trastuzumab with CD19+ B cells.

**Bispecific Antibodies**

Nowadays the FDA and EMA allow clinical trials where the therapeutic agent is a combination of two antibodies. Bispecific antibodies may be considered as a particular combination where both antibodies are in a single molecule. This type of antibodies allows to put in close proximity the tumor cell with an effector cell, a cytokine, etc., or to re-direct the immune response of cytotoxic T cells bypassing antigen recognition through the TCR (329).

On all the trials on hematological tumors using bispecific mAb reported here, the same bispecific mAb blinatumomab (bispecific CD19-CD3) was used in different combinations. An example combines blinatumomab with the anti-CD20 mAb rituximab, for non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia (NCT02003222). The rationale is to target the CD20+ B cells, while putting in close contact T cells (CD3+) with CD19+ B cells, to mount a strong cytotoxic T cell response. The rest of the trials from this group, all of them combine mAb targeting immune-checkpoints (CTLA-4, PD-1, or PD-L1) with the bispecific antibodies. These include blinatumomab in relapsed or refractory precursor B-lymphoblastic leukemia (NCT02879695) or for relapsed or refractory B cell acute lymphoblastic leukemia (NCT03160079). The rationale for these trials is to avoid the suppression of antitumor responses, while putting in close contact T cells (CD3+) with CD19+ B cells.

Bispecific antibodies in combination have also been used for the treatment of solid tumors. For most of the examples, one of the arms of the bispecific mAb identifies a tumor-associated antigen, such as the bispecific antibody RO6958688 (bispecific CD3-CEA) combined with atezolizumab, for the treatment of advanced and metastatic solid tumors (NCT02650713). The bispecific antibody RO6958688 (253, 254) recognizes, on the one side, the CD3 molecule of the TCR and, on the other side, the CEA, an antigen overexpressed in several tumors. The rationale of the trial is to block the binding of PD-L1 to its receptor avoiding the suppression of antitumor responses, while putting in close contact T cells (CD3+) with the CEA+ tumor cells, inducing a strong T cell activation which may result in a potent antitumor CTL response. Similarly, solid tumors were treated with atezolizumab in combination with bevacizumab or with vanucizumab, a bispecific mAb that simultaneously targets VEGF and Ang-2 (NCT02715531). This treatment aims to block the immune checkpoint suppression while inhibiting angiogenesis.

Another example of targeting tumor-associated antigens is the use of in vitro-activated T cells armed with GD2Bi-aATC, a bispecific antibody that recognizes CD3 and GD2 (231, 232), in combination with IL-2 and GM-CSF in patients with neuroblastoma or osteosarcoma (NCT02173093). The rationale of this study is to generate in vitro activated T cells that are infused in the patient after binding to the bispecific mAb, which will direct them to the tumor, generating a potent CTL response to kill tumor cells. Exogenous IL-2 and GM-CSF are added to maintain these cells and generate an inflammatory environment surrounding the tumor. In addition, another approach that has been used is to combine the anti-HER2 antibody trastuzumab with CD19+ B cells.
with a bispecific MM-11 mAb anti-ErbB2/anti-ErbB3 mAb (241) for the treatment of HER2+ breast cancer (NCT01097460). The aim is to simultaneously inhibit signaling through this family of tyrosine kinase receptors.

Another approach is to use bispecific mAb to inhibit angiogenesis in solid tumors. The two examples we describe use the bispecific mAb vanucizumab (VEGF-A/Ang-2). In one of them, it is used in combination with RO7009789 (255), an antibody with immunostimulatory effects that recognizes CD40, a member of the TNF receptor superfamily, for the treatment of metastatic solid tumors (NCT02665416). In the other example, it is used either alone or in combination with atezolizumab (PD-L1) in advanced or metastatic solid tumors (NCT01688206). The rationale for both cases is to either use an anti-CD40 agonist or an anti-checkpoint antibody to burst the antitumor immune response, while inhibiting simultaneously angiogenesis by blocking the VEGF-A/VEGFR- and Ang-2/Tie2-signaling pathways.

**Antibodies with Immunomodulatory Effects**

In a clinical trial for metastatic colorectal cancer, imalumab (BAX69) (233), a mAb that identifies MIF is used in combination with panitumumab (NCT02448810). BAX69 abrogates MIF signaling and MIF-mediated secretion of cytokines (IL-1β, TNF-α, etc.) and inhibits proliferation of MIF overexpressing tumor cells, together with the antiproliferative effects of panitumumab (anti-EGFR mAb).

Other examples, used for solid tumors, combine nivolumab with cabiralizumab, an anti-colony-stimulating factor 1 receptor (CSF1R) mAb, which inhibits binding of its ligands (CSF-1 and IL-34), blocking the production of inflammatory mediators by macrophages and monocytes and preventing osteoclast activation (NCT02526017; NCT03158272). The aim is to inhibit the tumor-induced immune suppression with nivolumab, and to block with cabiralizumab the recruitment of CSF1R-dependent tumor-associated macrophages (TAMs). Cabiralizumab also enhances T cell infiltration and antitumor T cell immune responses.

Another immunomodulatory antibody, anti-CSF-1R (BMS-986179) (209–211), has been used in combination with nivolumab on advanced or spread solid cancers (NCT02754141). In this case, the use of an antibody against the cell surface enzyme CD73 turns out to be very interesting. CD73 is overexpressed in many tumors and catalyzes the conversion of extracellular nucleotides into nucleosides, generating adenosine (211). The anti-CSF-1R antibody prevents the conversion of AMP to adenosine, which releases the inhibition of T cell, DC, and NK activities, induces the activation of macrophages, and reduces the activity of both myeloid-derived suppressor cells and regulatory T cells (209–211). This treatment was designed to abrogate the immunosuppressor effects of both, the immune checkpoint with nivolumab and the metabolic checkpoint with BMS-986179.

In addition to antibodies that release the inhibitory effects of immune-checkpoints, there are other antibodies that are able to directly activate the immune response. The following examples represent clinical trials where these immunostimulatory antibodies are used. One of them combines avelumab, which suppresses the signaling through negative immune checkpoints, with either the anti-cytokine antibody PD-0360324 (anti-CSF-1 mAb) (248); or with the immunostimulatory antibodies PF-04518600 (anti-OX40 mAb), or utomilumab (an anti-CD137 mAb) (262) (NCT02554812); whereas another combines the anti-OX40 mAb (MOXR0916) with atezolizumab in locally advanced or metastatic solid tumors. (NCT02410512). The aim is to inhibit the PD-1/PD-L1 axis (avelumab or atezolizumab), simultaneously bursting the immune response through OX-40, CD137, or blocking TAMs generation with the anti-CFS-1 (Aspelagh, 2016). A similar strategy uses atezolizumab in combination with varilumab (an agonistic anti-CD27 mAb), which results in an increase of the CTL response against CD27 ligands expressed on tumor cells (NCT02543645).

The anti-CD40 mAb RO7009789 activates and triggers proliferation of antigen-presenting cells (APC) and activates B and T cells, resulting in an enhanced immune response. When CD40 is expressed in solid tumor cells, RO7009789 leads to apoptosis and decreased tumor growth. This antibody in combination with the CSF1R inhibitory antibody emactuzumab has been used for the treatment of advanced solid tumors (225) (NCT02760797). Related examples combine anti-CD40 mAb either with nivolumab for the treatment of metastatic pancreatic adenocarcinoma (NCT03214250) or with the bispecific antibody vanucizumab (anti-VEGF-A and anti-Ang-2) (NCT02665416). The rationale is to activate the immune response through CD40 while inhibiting the angiogenesis blocking the binding of VEGF-A and Ang-2 to their receptors.

**Adjuvants and other Immunostimulatory Agents**

Another possible strategy is to combine therapeutic antibodies with molecules carrying repeated structural motifs that cannot be synthesized by vertebrates, and bind to pattern recognition receptors present in cells from the innate arm of the immune system (i.e., beta glucan that binds the C-type lectin receptor Dectin-1). These molecules are able to regulate the threshold of the immune response as an adjuvant, changing the secreted cytokine expression pattern. A particular example of this type of agents is the use of an attenuated preparation of the BCG (Bacille Calmette–Guerin) strain of *Mycobacterium bovis*, with potential immunostimulatory activity for the treatment of patients with bladder cancer (330).

An example, combining mAb and adjuvants is the use of BTH1704 (212), an mAb against MUC1, an aberrantly glycosylated antigen overexpressed on the surface of a variety of cancer cells, in combination with a polysaccharide beta 1,3/1,6 glucan derived from the cell wall of *Saccharomyces cerevisiae* (PGG Beta-Glucan), for the treatment of patients with advanced pancreatic cancer (NCT02132403). The rationale of this trial is to directly target the tumor with the anti-MUC1 mAb, while unspecifically stimulate the immune response with beta glucan by binding to an alternate site on the neutrophil complement receptor 3 (CR3), priming the neutrophil to become cytotoxic after binding to...
complement on tumor cells via CR3. In addition, this agent may induce hematopoietic progenitor cell mobilization.

**Antibodies in Combination with Vaccines**

Tumor cells carry antigens which can be recognized as non-self by the immune system. In some cases, however, the microenvironment in which these tumor antigens are presented do not allow to evoke an immune response. There is a plethora of possibilities to burst the antitumor immune response, one of them is to use tumor antigens as a vaccine. In the context of antitumor therapies, anti-idiotopic antibodies represent a particular type of vaccines.

Since the interaction of antibodies with other molecules is based on structural complementarity, antibodies that recognize the region of an antibody that interacts with its antigen (anti-idiotopic antibodies) might mimic the structure of this antigen (i.e., a tumor marker). Thus, the anti-idiotopic antibodies might act as an antitumor vaccine able to trigger a host immune response to kill tumor cells. Combining chemotherapy and radiotherapy with vaccine therapy may help to kill tumor cells more effectively.

An example of anti-idiotopic antibodies used as vaccines in antitumor therapy is abagovomab, an IgG1 anti-idiotype mAb, that functionally mimics the 3D structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125 (203). Its variable region acts as a surrogate antigen for CA-125, bestowing potential antineoplastic activity; it has been used in ovarian epithelial, fallopian tube, or peritoneal cancer (NCT00058435). Another example of vaccine therapy combines two anti-idiotopic antibodies, 11D10 (201) an mAb that mimics an epitope of the high molecular weight human milk fat globule glycoprotein, expressed at high levels by human breast and other tumor cells and 3H1 an mAb that mimics an epitope of the tumor-associated protein CEA (199). This combination has been used for the treatment of colorectal cancer metastatic to the liver (NCT00037348). The 11D10 mAb has also been used in other combinations, for example, with a GD2 anti-idiotype mAb vaccine, together with chemotherapy and radiotherapy, for the treatment of limited-stage SCLC (NCT00045617).

A study combining the anti-idiotopic mAb abagovomab, which mimics a specific epitope on CA-125 with stereotactic body radiation therapy (SBRT), chemotherapy, and the synthetic antiviral agent nelfinavir mesylate, which selectively binds to and inhibits human immunodeficiency virus protease, has been used for the treatment of locally advanced pancreatic cancer (NCT01959672).

Currently, other types of vaccines are being used with mAb in combination with agents that allow to evoke an immune response against tumor antigens. The mAb in these combinations may strengthen the evoked immune response. For the examples described below, the combination contains antibodies that either disrupt the PD-1/PDL-1 axis or that block the binding of B7-1 and B7-2 to CTLA-4 allowing T cell co-stimulatory signals and activation, unless otherwise specified. One example is the treatment with a peptide from Wilms tumor 1 antigen on recurrent ovarian cancer (NCT02737787). Another, more complex example is to administrate the peptide vaccine PVX-410 (derived from X-box-binding protein 1-unsplited XBP1-US, XBP1-spliced syndecan-1, and CS1), to treat triple-negative breast cancer tumors (NCT02826434). A third example uses a HER2 intracellular domain peptide in combination with the polysaccharide-K as adjuvant, in HER2\(^{+}\) recurrent breast cancer patients, which are receiving pertuzumab or trastuzumab (NCT01922921). The rationale for this trial is to combine the effects of the anti-HER2 mAb with using a HER2 peptide to switch the B and T cell responses through APC activation. Otherwise, peptides could be presented as a fusion protein, such as in CIMAvax vaccine (EGF-rP64K/Montanide ISA 51), which triggers a strong humoral immune response against EGF and has been used in NSCLC (NCT02955290). There are also personalized neoantigen cancer vaccines, such as NeoVax for the treatment of high-risk renal cell carcinoma (NCT02950766).

Another approach to generate vaccines is to use modified virus such as Ad-CEA vaccine, an oncolytic adenosivirus encoding an epitope of human CEA (331), used for the treatment of patients with previously untreated metastatic colorectal cancer (NCT03050814). This vaccine may induce both humoral and cellular immune responses against CEA\(^{+}\) tumor cells. A different example uses the CV301 (CEA-MUC-1-TRICOM Vaccine) viral vaccine, which contains a version of the recombinant vaccinia viral vector and a recombinant fowlpox viral vector encoding both CEA and MUC-1, in combination with TRICOM [co-stimulatory molecules, B7-1, intracellular adhesion molecule 1 (ICAM-1), and LFA-3] (332). It may enhance presentation of CEA and MUC-1 to APC and subsequently a CTL response against the tumor cells, it has been used in previously treated NSCLC (NCT02840994). A similar approach has been evaluated for the treatment of prostate cancer using a recombinant vaccinia virus encoding a modified peptide of the prostate-specific antigen and TRICOM (NCT00113984). This viral vaccine may enhance antigen presentation and may activate a CTL response.

Attenuated bacteria have also been used as carriers for antitumor vaccines. For example, the attenuated Listeria ADXS11-001 encoding a papillomavirus type 16 E7 fused to a non-hemolytic listeriolysin O protein, it has been used for the treatment of cervical and Head and Neck Cancer (HNSCC) (NCT02291055). The rationale is to mount a CTL response against cancer cells overexpressing the cell surface glycoprotein HPV 16 E7, overexpressed in the majority of cervical cancer cells.

More sophisticated approaches use tumor vaccines, such as GM.CD40L, which is a cell-based vaccine composed of irradiated tumor cells transduced with GM-CSF and CD40-ligand (CD40L) genes (333). Upon administration, this vaccine may stimulate an antitumoral DC-mediated immune response, it has been used in lung adenocarcinomas (NCT02466568). Another example that does not use anti-checkpoint antibodies but combines the anti-HER2 mAb trastuzumab with a cell-based vaccine, consisting of two irradiated allogeneic mammary carcinoma cell lines genetically modified to secrete human GM-CSF, has been used for the treatment of HER2\(^{+}\) metastatic breast tumors (NCT00399529). An additional example of cell-based vaccines uses GVAX (334), a pancreatic cancer vaccine and IMC-CS4, a macrophage targeting
mAb (CSF1R inhibitor) for the treatment of pancreatic adenocarcinomas (234). GVAX is composed of irradiated, whole tumor cells (autologous or allogeneic), genetically modified to secrete GM-CSF (NCT03153410).

The immune response against the tumor can be busted using also DNA, RNA, or liposome-based vaccines. As an example, triple-negative breast cancers have been treated with neoantigen DNA vaccine combined with anti-immune-checkpoint antibodies (NCT03199040). Other vaccines use autologous DC loaded in vitro with Cytomegalovirus pp65-lysosomal-associated membrane protein mRNA as a vaccine, in combination with the anti-IL2R alpha mAb basiliximab (207), in glioblastoma multiform (NCT00626483). The rationale is to restore the number of immunosuppressive T regulatory cells during recovery from therapeutic temozolomide-induced lymphopenia, together with a synergistic enhancement of vaccine-driven CTL responses. Another study describes the use of the immuno-modulating mAb varilulumab (anti-CD27, TNFR family) in combination with a liposome-based vaccine consisting of two peptides from MUC1 and the toll-like receptor 4 encapsulated in liposomes (NCT02270372). This immunization stimulates both cellular and humoral responses.

Another clinical trial uses trastuzumab and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine for HER-2 breast tumors. This study will also test whether cyclophosphamide can eliminate the suppressive influence of regulatory T cells. The vaccine consists of two irradiated allogeneic mammary carcinoma cell lines genetically modified to secrete human GM-CSF (NCT03995929).

Pidilizumab (anti-PD-1) (250) in combination with a DC fusion vaccine, following autologous stem cell transplantation has been used on multiple myeloma (NCT01067287). The rationale is to disrupt the PD-1/PD-L1 axis, while vaccinating the patients with de DC fusion vaccine, which consists of DC fused to the patient's myeloma, where the myeloma antigens will be presented by HLA class I to CD8+ T cells, allowing their activation and mounting a CTL response. This is done on patients after an autologous transplantation with HSCs. A similar approach uses nivolumab vaccine with autologous DCs pulsed with tumor lystate antigen, in patients with recurrent glioblastoma (NCT03014804).

Another study combines lymphodepletion with anti-CD45 mAb with a vaccine generated from autologous DC and Epstein Barr virus (EBV)-infected lymphoblastoid cell lines transduced with an LMP1/LMP2-expressing adenoviral vector, which are irradiated, and then used to stimulate and expand autologous CTL to produce LMP1-/LMP2-specific CTL ex vivo, for the treatment of EBV-nasopharyngeal carcinoma (NCT00515957). The rationale of this trial is to deplete autologous CD45+ cells, then generate a cell-based vaccine to activate ex vivo specific CTL that are then infused into the patient.

Other Strategies

In some approaches, a fusion protein between the antibody and a tumor antigen is used in combination with other therapies. For example, on the treatment of NY-ESO 1+ NSCLC, where atezolizumab was combined with both the adjuvant poly-ICLC (a synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid and poly-L-lysine double-stranded RNA) and DEC-205/NY-ESO-1 [CDX-1401, a fusion protein between a mAb directed against the endocytic DC receptor DEC-205, linked to the tumor-associated antigen (NY-ESO-1)] (NCT02495636) (217). Atezolizumab will inhibit immune checkpoints negative signals, while the internalization by DC of the mAb-antigen fusion protein may specifically deliver the NY-ESO-1 molecule and trigger a CTL response against cancer cells expressing this antigen. Simultaneously, the adjuvant may stimulate the release of cytophxic cytokines by inducing IFNgamma production. A similar approach, for the treatment of melanoma patients, using CDX-1401 combined with a neoantigen-based melanoma-poly-ICLC vaccine and a recombinant Flt3 Ligand (CDX-301) (NCT02129075). This treatment should boost the immune system to mount a CTL response against cancer cells expressing NY-ESO-1. In addition, the adjuvant may induce IFNgamma production and the recombinant Flt3 ligand may stimulate the proliferation and mobilization of bone marrow precursor cells, including CD34+ cells, and DCs.

An additional strategy would be to use scavengers of the ligand with low immunogenicity. For example, sEphB4-HAS, a human serum albumin (HAS) fused with the extracellular domain of tyrosine kinase ephrin type-B receptor 4 (sEphB4) is combined with pembrolizumab, for the treatment of NSCLC or HNSCC (NCT03049618). Pembrolizumab inhibits negative immune checkpoint signals, whereas EphB4-HSA is expected to decrease angiogenesis and cell growth of Efnb2 and/or EphB4 overexpressing tumor cells, while the albumin moiety will avoid renal clearance of the fusion protein, increasing its half-life without affecting immunogenicity.

Another strategy would be to target matrix enzymes required for tumor invasiveness. An example is the use of nivolumab combined with andecaliximab (GS-5745) (204, 205), an inhibitory mAb of matrix metalloproteinase 9 (MMP-9) in recurrent gastric or gastroesophageal junction adenocarcinomas (NCT02864381). Since MMP-9 activity is associated with tumor invasion and metastasis (335), the rationale is that andecaliximab will inhibit extracellular matrix protein degradation and angiogenesis, while nivolumab will interfere with the PD-1/PD-L1 axis.

Pembrolizumab (PD-1) was used in combination with CVA21 (CAVATAK™), coxsackievirus A21, a naturally occurring enterovirus with potential antitumor activity. This combination was used for advanced NSCLC (NCT02824965). CVA21, intra-tumor administered, targets and binds the ICAM-1 and decay acceleration factor, cell surface molecules, both overexpressed on certain malignant cells (336, 337). After entering the cells, the virus replicates causing cell lysis. This, together with the inhibition of the immune checkpoint, results in a reduction of tumor cell growth.

Another strategy combines conatumumab (220), an agonist mAb directed against the extracellular domain of human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2), also known as DR5, with the anti-IGF-1R mAb ganatumab, in patients with advanced solid tumors without disease progression whose previous studies were closed (NCT01327612). TRAIL-2 and IGF-1R are expressed by a variety of solid tumors.
and cancers of hematopoietic origin. Conatumumab mimics TRAIL activity, activating caspase cascades and inducing tumor cell apoptosis, while ganitumab inhibits IGF-1 binding and, therefore, the PI3K/Akt pathway. This treatment may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. Another clinical trial combining tigatuzumab, a mAb targeting the death receptor TRAIL-R2 with abraxane, an albumin-stabilized nanoparticle containing paclitaxel, non-covalently coated with the anti-CD20 mAb rituximab, in patients with metastatic, triple-negative breast cancer (NCT01307891). The relevance of the trial is that combines an anti-TRAIL-R2 mAb that induces death, while albumin stabilizes the complex, whereas rituximab allows to target paclitaxel to CD20+ cells, minimizing toxicity on normal cells. A strategy being used on EGFR+ tumors is to combine an anti-immune checkpoint antibody with the anti-EGFR mAb necitumumab (NCT02451930) or nimotuzumab (245) (NCT02947386). Or the same strategy, but using B-701, a neutralizing mAb directed against the fibroblast growth factor receptor type 3, in combination with azezolizumab in urothelial cell carcinoma (NCT03123055). One of the most sophisticated clinical trials combines chemotherapy, bevacizumab, avelumab, ALT-803 (IL-15 super agonist), aNK (allogenic human NK-92 cell line, expressing CD16 and IL-2), and GI-4000 (a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras) with the NANT pancreatic cancer vaccine (ETBX-011) containing a replication-defective adenoviral vector encoding a CEA epitope Ad5-CEA(6D), used for pancreatic cancer (NCT03136406). A clinical trial for colorectal cancer uses a similar combination of chemotherapy, nivolumab, avelumab bevacizumab, cetuximab, SBRT, haNK, ALT-803, and a cocktail of vaccines: ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, and GI-6301 (NCT03169777). The rationale for these two clinical trials is to hit the tumor simultaneously with a wide spectrum of the available tools against the tumor, where the concentration of each one of the agents can be decreased to minimize the unwanted effects on normal cells.

QUESTIONS AND QUERIES RAISED BY THE COMBINATIONS

We hope that we have been able to depict up to here, the huge complexity inherent to the use of therapeutic antibodies in combination with other biological agents for the treatment of cancer. Since most of the clinical trials described in this review are relatively recent (started during the last 7 years), many of them lack results in public databases, including the clinical trials database from NCI, or as published scientific manuscripts. This burst of clinical trials using antibodies in combinations with other biologicals is based on the positive results found by some combinations (anti-HER2 or anti-GD2 mAb), although the complexity increase in these combinations also implies an increase in the possibility of adverse side effects/increased toxicity or lack of additive or synergistic effects of the therapeutic agents. Initially, the therapeutic doses used for combinations were taken from the monotherapeutic trials, although in many cases, the non-toxic concentrations used in monotherapy, turn to be toxic in combinations, generating new toxicity profiles (338). This is of particular relevance when antibodies able to burst the antitumor immune response are used (either to inhibit the immune checkpoint proteins, to block inhibitory NK receptors or to trigger NK cells through activating receptors, etc.), which might lead to a dis-regulation of the immune response, an uncontrolled inflammatory response, and autoimmunity. This problem can also be related to an apparent lack of additive or synergistic effects of the therapeutic agents, where the potential clinical benefits of the combination could be overlooked by the initial toxicity of the mixture. Dose and schedule changes, however, can overcome the toxicity effects, allowing to demonstrate the enhanced clinical benefits of a particular combination (339). The use of CTLA-4 and PD-1 inhibitor antibodies in combination (nivolumab and ipilimumab), improved the treatment efficacy in advanced melanoma, as compared to monotherapies (340). Indeed, this combination has been approved in 2016 by the US FDA for the treatment of metastatic melanoma (341), despite the higher frequency and severity of adverse reactions of the combination, as compared to the corresponding monotherapies (340, 342–344).

It is interesting to note that a combination of TRC105 (carotuzumab, anti-endoglin antibody) with bevacizumab was used on a clinical trial for the treatment of patients with advanced cancer, where the combination was well tolerated and clinical activity was observed in a VEGF inhibitor-refractory population (NCT01332721) (345), the same combination failed to improve progression-free survival on patients with refractory metastatic renal cell cancer (NCT01727089) (346). These data clearly suggest that the problem does not strictly lie with the antibody combination, but rather it might be related to the tumor micro-environment, tumor type, the therapeutic approach used, or the clinical history of the patient.

Several examples of clinical trials where antibodies that have been used in combination with other biologicals, which were well tolerated and showed additive or synergistic therapeutic responses have been selected. These include a clinical trial for melanoma patients with low tumor infiltrating lymphocytes, an anti-PD-1 non-responsive phenotype. The combination of pembrolizumab with an intratumoral electroporation of a plasmid coding for interleukin 12 cDNA (pIL-12) showed a 40% clinical response with associated positive immune-based biomarker data and a safety profile (NCT02493361) (347), where the combination of pembrolizumab with the plasmid pIL-12 renders half of the patients responsive to the anti-PD-1. Another example that combines mAb with cytokines is a study of immune activation and antitumor activity in renal cancer of PEGylated human IL-10 (AM0010) in combination with pembrolizumab or nivolumab, the combinations were well tolerated, and CD8+ T cell activation was detected (NCT02009449) (348).

Other examples include a phase Ib study, oltertuzumab (TRU-016, an anti-CD37 mAb) in combination with rituximab and bendamustine, which was well tolerated and induced therapeutic responses in the majority of patients with relapsed indolent B-non-Hodgkin lymphoma (NCT01317901) (349). Similarly, the combination of pidilizumab plus rituximab was well tolerated and therapeutically active in patients with relapsed follicular lymphoma (350).
On a phase Ib study of utomilumab (PF-05082566, a 4-1BB/CD137 agonist), in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors had a confirmed complete or partial response in 26.1% of them. Pharmacokinetics and immunogenicity of both mAb were similar when administered alone or in combination. A trend toward higher levels of activated memory effector peripheral blood CD8+ T cells was observed in responders versus non-responders, supporting further investigation of this combination (NCT02179918) (262).

Other combinations include the anti-checkpoint antibody nivolumab in combination with an antibody that blocks the KIR inhibitory receptors in NK cells. On a phase I/II study of the NK-targeted antibody lirilumab (a fully human mAb that blocks inhibitory KIRs on NK cells) in combination with nivolumab in advanced HNSCC demonstrated, in preliminary results, clinical benefit, with deep and durable responses in some patients. This combination demonstrated a manageable safety profile similar to that observed with nivolumab monotherapy (NCT01714739) (347).

Another combination that might be interesting for the future of the field is the combination of oncolytic virus with anti-checkpoint antibodies. Indeed, preliminary results from several clinical trials using the oncolytic virus coxsackievirus A21 (CVA21, CAVATAK) in combination with ipilimumab (NCT01636882) (351) or pembrolizumab (NCT02043665) (348), for the treatment of patients with advanced cancer, showed that these combinations were generally well tolerated and induced antitumor activity. A phase II trial using intratumoral injection of the HF10 oncolytic virus, an attenuated, replication-competent mutant strain of herpes simplex virus type 1, and ipilimumab in patients with unresectable or metastatic melanoma showed therapeutic activity and the treatment was well tolerated (NCT02272855) (352).

For other clinical trials, on early phases, the combination is well tolerated, such as a dose escalation study of the OX40 agonist MOXR0916 and atezolizumab (anti-PD-L1 mAb) in patients with advanced solid tumors, using each agent at its recommended monotherapy dose, was well tolerated. (NCT02410512) (353).

Other clinical trials, including anti-checkpoint antibodies detect clear tumor regression, although with a toxicity higher than reasonable. This is the case for a clinical trial were BMS-986016 (anti-LAG-3 mAb) in combination with nivolumab was administered to patients with hematologic and solid malignancies. Preliminary results demonstrated objective tumor regressions, concomitant with the toxicity characteristic of immune checkpoint blockers (NCT02061761, NCT01968109) (348).

On another group of clinical trials, the main characteristic is that although they are well tolerated in general, they failed to provide significant additive/synergistic therapeutic effects. This is the case of a clinical trial where urelumab (a CD137 agonist), in combination with nivolumab was used for the treatment of hematologic and solid tumor malignancies. This combination did not provide significant additive/synergistic clinical benefits at the doses evaluated (NCT01471210, NCT02253992) (351). In another, urelumab in combination with rituximab or cetuximab was used in patients with refractory lymphoma or selected advanced solid tumors. Although the combinations were safe and well tolerated, with minimal evidence of liver toxicity, they did not demonstrate substantial enhancement of clinical responses or lead to intratumoral immune modulation in these tumor settings (NCT01775631, NCT02110082) (348).

Finally, there are a couple of selected clinical trials using combinations of antibodies and other biologics that were toxic or had to be terminated on overall benefit–risk assessment. These include a clinical trial with patients with advanced solid tumors, which were treated with a combination of MDX-447 [a bispecific mAb directed to FcγRI (CD64) and EGFR] with G-CSF; although the bispecific mAb alone was well tolerated, the combination was not well tolerated and precluded meaningful dose escalation on a phase I clinical trial (354). A second example is a phase II study of imalumab [BAX69, an anti-oxidized macrophage MIF (oxMIF)] and 5-FU/Leucovorin or Panitumumab (anti-EGFR mAb), versus the standard of care in metastatic colorectal cancer patients, which was terminated (February, 2017) based on overall benefit–risk assessment (NCT02448810), although it was initially reported that this combination was generally safe and well tolerated (355).

The problems that arose with using therapeutic antibodies in combinations has led the Society for Immunotherapy of Cancer to name a Combination Immunotherapy Task Force to identify and prioritize the most promising prospects for combinatorial approaches as well as to address the challenges associated with developing these strategies (339). Furthermore, it seems clear by now, that an improved understanding of pharmacodynamic effects of each agent within a combination will support the rational development of immune-based combinations for cancer treatment (356).

CONCLUSION

The broad variety of clinical trials summarized here presents the overwhelming complexity of the use of antibody in combinations for cancer treatments. The antibodies used either interfere with a ligand–receptor interaction, blocking a signaling pathway relevant for tumor growth, or identify tumor-associated antigens, where they somehow induce the death of the tumor cells by ADCC, CDC, and ADCP or directly inducing apoptosis. If the antibodies by themselves cannot kill the tumor cells, they can be conjugated to cytotoxic drugs to exert this function, or directly coupled to radio-labeled agents, where they trigger radiolysis. These antibodies can be combined with other antibodies that rather than directed against the tumor cells, identify targets on the tumor environment. These include antibodies that inhibit tumor-induced vascularization, or antibodies against cells or molecules involved in the immune response. A turning point was the use of mAb that block PD-L1/PD-1 interaction, or anti-CTLA-4 mAb; all of them disrupting the tumor-induced suppression of antitumor immune responses. In addition, mAb are used in combination with vaccines with the aim of evoking an antitumor response, either against a single tumor antigen or against a broad spectrum of antigens, for example when using irradiated tumor cells expressing pro-inflammatory cytokines.

It is obvious that there are many challenges to be solved regarding antibodies in combinations as antitumor therapeutic
agents. One of the most relevant challenges is the possible increase of toxicity of the combinations, concomitant with an increased complexity of the trials. This has to be carefully evaluated for each combination to identify the conditions giving the highest efficacy/toxicity ratio. This is of particular interest when the aim is to burst the antitumor host immune response, where a small response could fail to kill the tumor, but an over-response could lead to unwanted inflammatory or autoimmune processes. Another relevant challenge to be solved is the identification of new/additional biomarkers that would allow a personalized follow-up of the patient’s status, which would be required due to the tumor and the patient’s genotypic and phenotypic differences.

The current clinical trials suggest that in the future anti-cancer therapies will combine antibodies that block signaling cascades, or identify tumor-associated antigens with others that disrupt the tumor-induced immunosuppression, together with vaccines that evoke an antitumor immune response, activated effector cells or CAR T cells. These combinations could also contain anti-cytokine antibodies, or cytokines, to burst the immune response. The aim will be to directly target tumor antigens or signal pathways, and at the same time interfere with the “immune history” of the organism, to make the patient’s own body aware of the tumor presence and simultaneously help it to make a strong antitumor response. Thus, it will be the patient’s immune response against the tumor the ultimate mechanism responsible for the cure of cancer.

**REFERENCES**

1. Ayayar BV, Arora S, O’Kennedy R. Coming-of-age of antibodies in cancer therapeutics. Trends Pharmacol Sci (2016) 37(12):1009–28. doi:10.1016/j.tips.2016.09.005
2. Chiavenna SM, Jaworski JP, Vendrell A. State of the art in anti-cancer mAbs. J Biomed Sci (2017) 24(15):1. doi:10.1186/s12929-016-0311-y
3. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 14:73. doi:10.1186/s12916-016-0623-5
4. Levy O. Therapeutic antibodies: past, present and future. Nat Rev Immunol (2010) 10(3):297. doi:10.1038/nri2763
5. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer (2012) 12(4):278–87. doi:10.1038/nrc3236
6. Weiner LM, Sunara R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 10(5):317–27. doi:10.1038/nri2744
7. Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Clin North Am (2012) 26(3):447–81. viii. doi:10.1016/j.hcna.2012.02.013
8. Martín-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The expanding role of immunotherapy. Cancer Treat Rev (2017) 54:74–86. doi:10.1016/j.ctrv.2017.01.008
9. Schadenkopf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol (2015) 33(17):1889–94. doi:10.1200/JCO.2014.65.2736
10. Callahan MK, Wolchok JD. At the bedside: CTLA-4 and PD-1–blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 94(1):41–53. doi:10.1189/jlb.5RI0116-013RR
11. Schuurman J, Parren PW. Editorial overview: special section: new concepts in antibody therapeutics: what’s in store for antibody therapy? Curr Opin Immunol (2016) 40:viii–xiii. doi:10.1016/j.coii.2016.04.001
12. Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer (2015) 15(8):457–72. doi:10.1038/nrc3973
13. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 14(8):561–84. doi:10.1038/nrd4591
14. Henricks LM, Schellens JH, Huitema AD, Beijnen JH. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat Rev (2015) 41(10):859–67. doi:10.1016/j.ctrrev.2015.10.008
15. Vignel AE, Johnson DB, Richmond A. Combinatorial approach to cancer immunotherapy: strength in numbers. J Leukoc Biol (2016) 100(2):275–90. doi:10.1189/jlb.SR1106-013RR
16. Morrissey KM, Yuraszek TM, Li CC, Zhang Y, Kasicaynula S. Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin Transl Sci (2016) 9(2):89–104. doi:10.1111/cts.12391
17. Saxiyanarayan V, Neelapu SS. Cancer immunotherapy: strategies for personalization and combinatorial approaches. Mol Oncol (2015) 9(10):2043–53. doi:10.1016/j.molonc.2015.10.009
18. Khalid DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 13(5):273–90. doi:10.1038/nrclinonc.2016.25
19. Ni L, Dong C. New checkpoints in cancer immunotherapy. Immunol Rev (2017) 276(1):52–65. doi:10.1111/imr.12524
20. Romano G, Gawlinski A. New frontiers in oncology: immune checkpoint inhibitors in combination therapy. Drugs Today (Bart) (2017) 53(2):103–15. doi:10.1358/dot.2017.53.2.2592798
21. Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open (2017) 2(2):e000213. doi:10.1136/esmoopen-2017-000213
22. Pankow MJ, Liu Y, Bagchi S, Lesokhin AM. Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig (2017) 4:32. doi:10.21037/sci.2017.03.04
23. Goodman A, Patel SP, Kurzrock R. PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol (2017) 14(4):203–20. doi:10.1038/nrclinonc.2016.168
24. Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother (2017) 66(5):531–64. doi:10.1007/s00262-017-1954-6

**AUTHOR CONTRIBUTIONS**

All authors contributed to drafting, revising, and approving the final article.

**ACKNOWLEDGMENTS**

The authors thank all the members of their laboratories for critical reading of the manuscript and helpful suggestions.

**FUNDING**

The work in the author’s laboratories was partially supported by grants from the CSIC (PIE-201420E109, to LK), the PN2014-A from the ISCIII (PI14/00703, co-financed by FEDER funds from the EU, Operative program on Intelligent Growth 2014-2020, to LK), and from the Spanish Ministry of Economy, Industry and Competitiveness (RTC-2015-3786-1 to LK and JG-S, and RTC-2015-3846-1 to JG-S), both co-financed by FEDER funds from the EU.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at http://www.frontiersin.org/articles/10.3389/fimmu.2017.01804/full#supplementary-material.
25. Aris M, Mordoh J, Barrio MM. Immunomodulatory monoclonal anti-bodies in combined immunotherapy trials for cutaneous melanoma. Front Immunol (2017) 8:1024. doi:10.3389/fimmu.2017.01024

26. Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol (2017) 8:1509. doi:10.3389/fimmu.2017.01509

27. Santamaria S, Delgado M, Kremer L, Garcia-Sanz JA. Will a mAb-based immunotherapy directed against cancer stem cells be feasible? Front Immunol (2017) 8:1509. doi:10.3389/fimmu.2017.01509

28. Papaioannou NE, Beniati OV, Vitsos P, Titolisou N, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med (2016) 4(4):261. doi:10.21037/atm.2016.04.01

29. Brody J, Kohrt H, Marabelle A, Levy R. Active and passive immunotherapy for lymphoma: proving principles and improving results. jClin Oncol (2011) 29(14):1864–75. doi:10.1200/JCO.2010.33.4623

30. Reichert JM. Antibodies to watch in 2017. MAbs (2017) 9(2):167–81. doi:10.1080/19420862.2016.1269580

31. Andrick BJ, Gandhi A. Olaratumab: a novel platelet-derived growth factor receptor alpha-inhibitor for advanced soft tissue sarcoma. Ann Pharmacother (2017) 51(12):1090–8. doi:10.1177/0003461617723935

32. Chioereg EA, Sweeney C, Youssoufian H, Qin A, Dostabhattani A, Loizos N, et al. Phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 73(3):595–604. doi:10.1007/s00280-014-2398-9

33. Deshpande HA, Cecchini M, Ni Choileain S, Jones R. Olaratumab for the treatment of advanced cancer. Lancet Oncol (2017) 18(6):743–54. doi:10.1016/S1470-2045(17)30313-3

34. Dienstmann R, Tabernerio J. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investig Drugs (2010) 11(12):1434–41.

35. Genova C, Hirsch FR. Clinical potential of necitumumab in non-small cell lung carcinoma. Onco Targets Ther (2016) 9:3427–37. doi:10.2147/OTT. S114039

36. Recondo G Jr, de la Vega M, Galanternik F, Diaz-Canton E, Leone BA, Leone JP. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-drug conjugate. Cancer Res (2008) 68(22):9280–90. doi:10.1158/0008-5472.CAN-08-1776

37. Reck M, Thomas M, Kropf-Sanchen C, Mezger J, Socinski MA, Depenbrock H, et al. Necitumumab plus gemcitabine and cisplatin as first-line therapy in patients with stage IV EGFR-expressing squamous non-small-cell lung cancer: German subgroup data from an open-label, randomized controlled phase 3 study (SQUIRE). Oncol Res Treat (2016) 39(9):539–47. doi:10.1159/000448085

38. Battaglin D, Dadduzzi V, Bergamo F, Manai C, Schirripa M, Lonardi S, et al. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opin Biol Ther (2017) 17(10):1–12. doi:10.1080/14712598.2017.1356815

39. Cohenuram M, Saif MW. Panitumumab: the first fully human monoclonal antibody: from the bench to the clinic. Antibodies (2007) 18(1):7–15. doi:10.1097/CAD.0b013e3280b06ecd

40. Tay RY, Wong R, Hawkes EA. Treatment of metastatic colorectal cancer: focus on panitumumab. Cancer Manag Res (2015) 7:189–98. doi:10.2147/CMR.S71821

41. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF; a fully human anti-EGF receptor monoclonal antibody for cancer therapy. Crit Rev Pharmacol Pharmacother (2004) 57(7):1621–33. doi:10.1517/14656566.5.7.1621

42. Carrato A, Abad A, Massuti B, Gravales C, Escudero P, Longo-Munoz F, et al. First-line panitumumab plus FOLFIRX or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: a randomised, phase II trial (PLANE-00): results of phase II portion of a randomised controlled phase 3 trial. Br J Cancer (2016) 115(10):1223–33. doi:10.1038/jbc.2016.313

43. Matsuki S, Iijichi K, Nakanishi H, Hasegawa Y, Ogawa T, Murakami S. Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma. Mol Clin Oncol (2013) 15(5):918–24. doi:10.3892/mco.2013.159

44. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of first-line chemotherapy combined with cetuxi-mab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA (2017) 317(23):2392–401. doi:10.1001/jama.2017.7105
Corraliza-Gorjón et al.

70. Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the trans-

69. Arrieta O, Zatarain-Barron ZL, Cardona AF, Carmona A, Lopez-Mejia M.

68. Zhao Z, Li J, Ye R, Wu X, Gao L, Niu B. A phase II clinical study of com-

67. Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R,

64. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development

65. Levin PA, Dowell JE. Spotlight on bevacizumab and its potential in the

63. Mekhitarian K, Zou L, Hsu ST, Acosta E, Lipton A. A study of the monoclonal

62. van der Valk PA, Postma GJ, Irion MC, Hofmaier K, van Besien K.

61. Albitar M, Yanik M, Klimstra DS, Park J, Benson AB, Jr., et al. Progesterone

60. Puy J, Bidignani F, Varadhchandra A, et al. Pembrolizumab in patients with

59. Doretti D, Logli SL, Colombo P. Pembrolizumab in patients with melanoma

58. Yang JC, Taube JM, Hodi FS, Schachter J, Gettinger SN, Brahmer JR, et al.

57. Keswani R, Gonen M, Hecht J, Fruhwald CM, Gajewski TF, et al. Pembroliza-

56. Pardoll D. The blockade of immune checkpoints in cancer immunotherapy.

55. Atkins M, Spitz G, Mok T, et al. A randomized phase III trial of pembrolizumab

54. Rathindranath Z, et al. PD-1/PD-L1 blockade: the current status.

53. Brahmer JR, Plunkett W,nP, Taube J, et al. Nivolumab: an immunotherapeutic

52. Nishio M, Nakagawa N, Higashiyama K, et al. Nivolumab for Japanese

51. McDermott DF, Atkinson V, Schmaltz S, et al. Pembrolizumab in patients with

50. Altwerger G, Guglielmi C, Herrero-Fernandez I, et al. Pembrolizumab in

49. Levy RL, Huang A, Boggon TJ, et al. Pembrolizumab and ipilimumab in the

48. Holland SM, et al. Pembrolizumab in patients with advanced melanoma:

47. De Rie MA, et al. A randomized phase III, multicenter trial to compare the

46. Brahmer JR, believers N, et al. Nivolumab: observations of long-term

45. Breslin ME, et al. Durable response to nivolumab in a patient with a non-

44. Maio M, et al. Nivolumab for the treatment of advanced renal cell

43. Patel MR, et al. Nivolumab in combination with ipilimumab as first-line

42. Robert C, et al. Nivolumab plus ipilimumab versus ipilimumab alone in

41. Robert C, et al. Nivolumab in patients with advanced melanoma with or

40. Robert C, et al. Nivolumab in previously treated patients with advanced

39. Robert C, et al. Nivolumab monotherapy for advanced melanoma:

38. Robert C, et al. Nivolumab: an immunotherapeutic agent for advanced

37. Robert C, et al. Nivolumab in combination with ipilimumab for the treatment

36. Robert C, et al. Nivolumab for the treatment of advanced melanoma:

35. Robert C, et al. Nivolumab monotherapy for previously untreated patients

34. Robert C, et al. Nivolumab monotherapy in patients with advanced

33. Robert C, et al. Nivolumab monotherapy for previously untreated patients

32. Robert C, et al. Nivolumab: final updated results.

31. Robert C, et al. Nivolumab compared with ipilimumab as first-line treatment

30. Robert C, et al. Nivolumab in patients with advanced melanoma: updated

29. Robert C, et al. Nivolumab in previously treated patients with advanced

28. Robert C, et al. Nivolumab monotherapy in patients with advanced

27. Robert C, et al. Nivolumab: 1-year follow-up of open-label, multicenter,

26. Robert C, et al. Nivolumab: an immunotherapeutic agent for advanced

25. Robert C, et al. Nivolumab as monotherapy for advanced melanoma:

24. Robert C, et al. Nivolumab as monotherapy for advanced melanoma:

23. Robert C, et al. Nivolumab as monotherapy for advanced melanoma:

22. Robert C, et al. Nivolumab as monotherapy for advanced melanoma:

21. Robert C, et al. Nivolumab in combination with ipilimumab for the treatment

20. Robert C, et al. Nivolumab: monotherapy in patients with advanced

19. Robert C, et al. Nivolumab: an immunotherapeutic agent for advanced

18. Robert C, et al. Nivolumab in combination with ipilimumab as first-line

17. Robert C, et al. Nivolumab in patients with advanced melanoma: updated

16. Robert C, et al. Nivolumab compared with ipilimumab as first-line treatment

15. Robert C, et al. Nivolumab: final updated results.

14. Robert C, et al. Nivolumab in patients with advanced melanoma: updated

13. Robert C, et al. Nivolumab: 1-year follow-up of open-label, multicenter,

12. Robert C, et al. Nivolumab as monotherapy for advanced melanoma:

11. Robert C, et al. Nivolumab as monotherapy for advanced melanoma:

10. Robert C, et al. Nivolumab in combination with ipilimumab for the treatment

9. Robert C, et al. Nivolumab: monotherapy in patients with advanced

8. Robert C, et al. Nivolumab in patients with advanced melanoma: updated

7. Robert C, et al. Nivolumab compared with ipilimumab as first-line treatment

6. Robert C, et al. Nivolumab in patients with advanced melanoma: updated

5. Robert C, et al. Nivolumab: 1-year follow-up of open-label, multicenter,

4. Robert C, et al. Nivolumab as monotherapy for advanced melanoma:

3. Robert C, et al. Nivolumab: an immunotherapeutic agent for advanced

2. Robert C, et al. Nivolumab in combination with ipilimumab as first-line

1. Robert C, et al. Nivolumab: final updated results.
102. Burkiwicz JS, Scarpace SL, Bruce SP. Denosumab in osteoporosis and oncology. *Ann Pharmacother* (2009) 43(9):1445–55. doi:10.1345/aph.1H1102

103. Prommer E. Palliative oncology: denosumab. *J Hosp Palliat Care* (2015) 32(5):568–72. doi:10.1177/1949999114539035

104. Savvidou OD, Bola IK, Chloros GD, Panapatassiou J, Koutsouriadis P, Papageopoulos PJ. Denosumab: current use in the treatment of primary bone tumors. *Orthopedics* (2017) 40(4):204–10. doi:10.3928/01474472-20170627-04

105. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. *Lancet Oncol* (2016) 17(9):1306–16. doi:10.1016/S1470-2045(16)30173-5

106. Feng EE, Erickson H, Lutz RJ, Whiteman KR, Jones G, Kovtun Y, et al. Design of coltumab ravtansine, a CD19-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies: structure-activity relationships and preclinical evaluation. *Mol Pharm* (2015) 12(6):1703–16. doi:10.1021/acs.molpharmaceut.5b00175

107. O’Sullivan Coyne G, Burotto M. MABp1 for the treatment of colorectal cancer. *Expert Opin Biol Ther* (2017) 17(9):1155–61. doi:10.1080/14712598.2017.1347631

108. Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocis J, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* (2017) 18(2):192–201. doi:10.1016/S1470-2045(17)30006-2

109. Bartholomew J, Washington T, Bergeron S, Nielson D, Saggio J, Quirk L. Dinituximab: a novel immunotherapy in the treatment of pediatric patients with high-risk neuroblastoma. *J Pediatr Oncol Nurs* (2016) 34(1):1–12. doi:10.1016/j.jpon.2014.11.001

110. Hoy SM. Dinituximab: a review in high-risk neuroblastoma. *Target Oncol* (2016) 11(2):247–53. doi:10.1007/s11786-015-0420-2

111. Soman G, Kallarakal AT, Michiel D, Yang X, Sapatrish N, Jiang H, et al. Analytical characterization of ch14.18: a mouse-human chimeric disialoganglioside-specific therapeutic antibody. *MAbs* (2012) 4(1):84–100. doi:10.4161/mabs.4.1.18566

112. Marachelian A, Desai A, Balis F, Katzenstein H, Qayed M, Armstrong M, et al. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. *Cancer Chemother Pharmacol* (2016) 77(2):405–12. doi:10.1007/s00280-015-0259-9

113. Adkins JC, Spencer CM. Edrecolomab (monoclonal antibody 17-1A). *Drugs* (1998) 56(4):619–26; discussion 27–8. doi:10.2165/00003495-19985604-00011

114. Frost EE, Biberfeld P, Christensson B, Pihlstedt P, Shetye J, Makower J, et al. Treatment of gastrointestinal tumors with MAb17-1A. *J Chemother* (1989) 1(4 Suppl):1209–11.

115. Gires O, Bauerle PA. EpCAM as a target in cancer therapy. *Target Oncol* (2017) 12(3):343–51. doi:10.1007/147529.2017.1334053

116. Schmoll HJ, Arnold D. When wishful thinking leads to a misty-eyed perspective. *Pharmacol Ther* (2012) 133(3):334–42. doi:10.1016/j.pharmthera.2012.07.011

117. Laurenti L, Innocenti I, Autore F, Sica S, Efremov DG. New developments at the neuroblastoma clinical trial landscape. *Oncologist* (2016) 18(1):568–72. doi:10.1634/theoncologist.2015-0076

118. Van den Berghe V, Wolters E, Mertens P, Debaillie T, Van Den Branden L, et al. Refractory indolent non-Hodgkin lymphoma treated in the phase III MAHOMAD trial: a single-arm phase 3b trial. *Ann Oncol* (2017) 28(10):2510–7. doi:10.1093/annonc/mdx150

119. Kaplan JB, Grischken M, Giles FJ. Blinatumomab for the treatment of acute lymphoblastic leukemia. *Invest New Drugs* (2015) 33(6):1277–9. doi:10.1007/s10637-015-0289-4

120. Nagorsen D, Kufer P, Bauereir PA, Bargou R. Blinatumomab: a historical perspective. *Pharmacol Ther* (2012) 133(3):334–42. doi:10.1016/j.pharmthera.2012.07.011

121. Sanders S, Stewart DA. Targeting non-Hodgkin lymphoma with blinatumomab. *Expert Opin Biol Ther* (2017) 17(8):1013–7. doi:10.1080/14712598.2017.1334053

122. Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. *J Clin Oncol* (2016) 34(10):1104–11. doi:10.1200/JCO.2014.39.1586
181. Joglekar-Javadekar M, Van Laere S, Bourne M, Moalwi M, Finetti P, Vermeulen PB, et al. Characterization and targeting of platelet-derived growth factor receptor alpha (PDGFRα) in inflammatory breast cancer (IBC). Noplasia (2017) 18(7):564–73. doi:10.5117/n.2017.03.002.

182. Yang WJ, Shen XI, Ma XX, Tan ZG, Song Y, Guo YT, et al. Correlation of human epidermal growth factor receptor protein expression and colorectal cancer. World J Gastroenterol (2015) 21(28):8687–96. doi:10.3748/wjg.v21.i28.8687.

183. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in neoplasia. J Cancer Res Ther (2012) 8(Suppl 1):S22–6. doi:10.4103/0974-7246.92303.

184. Schroder JM. Peptides and cytokines. Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X. Curr. Opin. Immunol. (2006) 18(5):655–60. doi:10.1016/j.coi.2006.05.018.

185. Wei S, Teitelbaum SL, Wang MW, Ross FP. Receptor activator of nuclear factor-kappa B ligand activates nuclear factor-kappa B in osteoclast precursors. J Bone Miner Res (2001) 16(10):1979–86. doi:10.1359/jbmr.2001.16.10.1979.

186. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal (2007) 19(10):2003–12. doi:10.1016/j.cellsig.2007.03.013.

187. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-angiogenic therapies. Genes Cancer (2011) 2(12):1097–105. doi:10.1177/1947668111423003.

188. NCBI. Available from: http://www.ncbi.nlm.nih.gov/protein.

189. Kosmaczewska A, Ciszak L, Bocko D, Frydecka I. Expression and functional significance of CTLA-4, a negative regulator of T cell activation. Arch Dermatol Res (2002) 294(5):397–402. doi:10.1007/s00403-002-0437-0.

190. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, et al. Abstract presented as oral presentation at ASCO 2014.

191. Wu L, Huang P, Wang F, Li D, Xie E, Zhang Y, et al. Relationship between MMP2 and clinicopathological parameters of urothelial carcinoma of the bladder. Cancer Immunother (2017) 1216292. doi:10.1080/2162402X.2016.1216292.

192. Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 33(5):231–7. doi:10.1016/j.it.2012.02.009.

193. Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol (2015) 8:44. doi:10.1186/s13045-014-0114-5.

194. Carriere MC, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D. Colony-stimulating factor 1 receptor (CSFIR) inhibitors in cancer therapy. Immunol J (2017) 51(1):53. doi:10.1186/s40425-017-0257-y.

195. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Mol Med (2014) 20(Suppl 1):S53–8. doi:10.2119/molmed.2014.00232.

196. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, et al. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 18(17):4820–9. doi:10.1158/1078-0432.CCR-12-0098.

197. Zheng B, Wong P, Yang N, Narla R, Burgess M, Escoubet L, et al. Abstract presented as oral presentation at ASCO 2014.

198. Marshall DC, Lyman SK, McAuley S, Kovalenko M, Spangler R, Liu C, et al. Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PLoS One (2015) 10(5):e0127063. doi:10.1371/journal.pone.0127063.

199. Appleby TC, Greenstein AE, Hung M, Liliccan A, Velasquez M, Villenesor AG, et al. Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9. J Biol Chem (2017) 292(16):6810–20. doi:10.1074/jbc.M116.760579.

200. Bellmunt J, Orsola A, Sonpavde G. Precision and predictive medicine in urothelial cancer: are we making progress? Eur Urol (2015) 68(4):547–9. doi:10.1016/j.eururo.2015.04.025.

201. Onrust SV, Wiseman LR, Basiliskimag. Drugs (1999) 57(2):207–13; discussion 4. doi:10.2165/00003495-1999597020-00006.

202. Zhao XY, Subramaniam B, Sarapa N, Goller S, Dinter H. Novel antibody therapeutics targeting mesothelin in solid tumors. Clin Cancer Drugs (2016) 3(2):76–86. doi:10.2126797x0366216218215744.

203. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res (2006) 12(18):5503–10. doi:10.1158/1078-0432.CCR-05-3410.

204. Marshall DC, Lyman SK, McAuley S, Kovalenko M, Spangler R, Liu C, et al. Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PLoS One (2015) 10(5):e0127063. doi:10.1371/journal.pone.0127063.

205. Silvestrini M, Scholz P, Wiedenmann B, Menard A. The targeted therapy of glioblastoma multiforme. World J Gastroenterol (2015) 21(28):8687–96. doi:10.3748/wjg.v21.i28.8687.
298. Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. Mabs (2013) 5(7):303–10. doi:10.1080/19420860.2015.1015799

299. Kamath AV, Iyer S. Challenges and advances in the assessment of the disposition of antibody-drug conjugates. Biopharm Drug Dispos (2016) 37(2):66–74. doi:10.1002/bdd.1957

300. Kamath AV, Iyer S. Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm Res (2015) 32(11):3470–9. doi:10.1007/s11095-014-1584-z

301. Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates-a new wave of cancer drugs. Bioorg Med Chem Lett (2014) 24(23):5357–63. doi:10.1016/j.bmolc.2014.10.021

302. de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol (2016) 40:14–23. doi:10.1016/j.coi.2016.02.008

303. Polakis P. Antibody drug conjugates for cancer therapy. Pharmaco Rev (2016) 68(1):3–19. doi:10.1124/ptr.900373

304. Rossin R, van Duijnhoven SM, Ten Hoeve W, Janssen HM, Kleijn LH, Hoeben FJ, et al. Triggered drug release from an antibody-drug conjugate using fast “click-to-release” chemistry in mice. Bioconjug Chem (2016) 27(7):1967–76. doi:10.1021/acs.bioconjchem.6b00231

305. Rossi A. Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer. Cancer Immunol Immunother (2017) 66(1):368–76. doi:10.1007/s00262-016-1621-0

306. Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMAAE) targeting GP1A1. Cancer Immunol Pharmacol (2007) 60(3):423–35. doi:10.1007/s00280-007-0490-2

307. Ramakrishna V, Sundarapandiyam K, Zhao B, Bylesjo M, Marsh HC, Keler T. Characterization of the human T cell response to in vitro CD27 costimulation with varililumab. J Immunother Cancer (2015) 3:3. doi:10.1186/s40425-015-0080-2

308. Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, et al. Safety and activity of varililumab, a novel and first-in-class anti-CD27 antibody, in patients with advanced solid tumors. J Clin Oncol (2015) 33(18):2028–36. doi:10.1200/JCO.2015.67.1508

309. Ab O, Whitteman KR, Bartle LM, Sun X, Singh R, Tavares D, et al. IMGN853, a folate receptor-alpha (FRα) targeting antibody-drug conjugate, exhibits its potent targeted antitumor activity against FRα-positive expressing tumors. Mol Cancer Ther (2015) 14(7):1605–13. doi:10.1158/1535-7163.MCT-14-1095

310. Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Mesothelin as a cancer therapeutic target. J Immunother Cancer (2017) 5(1):347. doi:10.1186/s40425-016-0086-6

311. List T, Neri D. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol (2013) 5:29–45. doi:10.2147/CPAA.S49231

312. Neri D, Sondel PM. Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol (2016) 40:96–102. doi:10.1016/j.coi.2016.03.006

313. Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today (2012) 17(11–12):583–90. doi:10.1038/drdiscov.2012.100

314. Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, et al. Intracellular adminstration of L-19-II/z-LNFV in stage III or stage IV MIA melanoma patients: results of a phase II study. Cancer Immunol Immunother (2015) 64(8):999–1009. doi:10.1007/s00262-015-1704-6

315. Danielli R, Patuzzi R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, et al. Intravenous administration of L-19-II/z-LNFV in stage III or stage IV MIA melanoma patients: results of a phase II study. Cancer Immunol Immunother (2014) 63(5):419–35. doi:10.1007/s00262-014-1523-1

316. Danielli R, Patuzzi R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, et al. Intravenous administration of L-19-II/z-LNFV in stage III or stage IV MIA melanoma patients: results of a phase II study. Cancer Immunol Immunother (2014) 63(5):419–35. doi:10.1007/s00262-014-1523-1

317. Danielli R, Patuzzi R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, et al. Intravenous administration of L-19-II/z-LNFV in stage III or stage IV MIA melanoma patients: results of a phase II study. Cancer Immunol Immunother (2014) 63(5):419–35. doi:10.1007/s00262-014-1523-1

318. Danielli R, Patuzzi R, Ruffini PA, Mauriuchi A, Gallino G, Patuzzi R, et al. Armed antibodies for cancer treatment: a promising tool in a changing era. Cancer Immunol Immunother (2014) 63(5):419–35. doi:10.1007/s00262-014-1523-1

319. Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, et al. Armed antibodies for cancer treatment. Curr Top Med Chem (2015) 15(4):670–82. doi:10.2174/1568026615666150757

320. Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist (2015) 20(6):660–73. doi:10.1634/theoncologist.2014-0465

321. Bumbaca D, Xiang H, Boswell CA, Port RE, Stanton SL, Mondloch EE, et al. Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue angiogenic sinks in mice. Br J Pharmacol (2014) 168(1):368–77. doi:10.1111/j.1365-201X.2013.13777.x

322. Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol (2016) 40:96–102. doi:10.1016/j.coi.2016.03.006

323. Bumbaca D, Xiang H, Boswell CA, Port RE, Stanton SL, Mondloch EE, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, using fast “click-to-release” chemistry in mice. Bioconjug Chem (2016) 27(3):47–55. doi:10.2147/OV.S56322

324. Danielli R, Patuzzi R, Ruffini PA, Mauriuchi A, Gallino G, Patuzzi R, et al. Armed antibodies for cancer treatment: a promising tool in a changing era. Cancer Immunol Immunother (2014) 63(5):419–35. doi:10.1007/s00262-014-1523-1
Combinations Using Therapeutic Antibodies for Cancer

337. Skelding KA, Barry RD, Shafren DR. Systemic targeting of metastatic human breast tumor xenografts by coxsackievirus A21. Breast Cancer Res 2019; 21:13(1):23–30. doi:10.1016/s1532-183x(10)50682-6

338. Kroschinsky F, Stolzel F, von Bonin S, Beutel G, Kochanek M, Kiel M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care (2017) 21(1):89. doi:10.1186/s13054-017-1678-1

339. Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer (2017) 5:16. doi:10.1186/s40425-017-0218-5

340. Wolchok JD, Clugger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol (2016) 13(8):473–86. doi:10.1038/nrclinonc.2016.58

341. Helissey C, Vicier C, Champiat S. The development of immunotherapy in older adults: new treatments, new toxicities? J Geriatr Oncol (2016) 7(5):325–33. doi:10.1016/j.jgo.2016.05.007

342. Hassel JC, Heinzerling L, Aberle J, Bahr O, Eigentler TK, Grimm MO, et al. Combined immune checkpoint blockade (anti-CTLA-4/anti-PD-1) and the impact of clinical settings on adverse drug reactions. Cancer Treat Rev (2017) 57:36–49. doi:10.1016/j.ctrv.2017.05.003

343. Spain L, Larkin J. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opin Biol Ther (2016) 16(3):389–96. doi:10.1517/17415502.2016.1141195

344. Gordon MS, Robert F, Matei D, Mendelson DS, Goldman JW, Chiorean EG, et al. An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res (2014) 20(23):5918–26. doi:10.1158/1078-0432.CCR-14-1143

345. Dorff TB, Longmate JA, Pal SK, Starler WM, Fishman MN, Vaishampayan UN, et al. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer (2017) 123(25):4566–73. doi:10.1002/cncr.30942

346. Althammer S, Steele K, Rebellato M, Tan TH, Wiestler T, Schmidt G, et al. 31st annual meeting and associated programs of the society for immunotherapy of cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016. J Immunother Cancer (2016) 4(Suppl 2):91. doi:10.1186/s40425-016-0191-4

347. Ager C, Reilly M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, et al. 31st annual meeting and associated programs of the society for immunotherapy of cancer (SITC 2016): part two. J Immunother Cancer (2016) 4(1):73. doi:10.1186/s40425-016-0173-6

348. Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, et al. Phase 1b study of ot tertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs (2014) 32(3):23–25. doi:10.1007/s10637-014-0125-2

349. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol (2014) 15(1):69–77. doi:10.1016/S1470-2045(13)70551-5

350. Lundqvist A, van Hoef V, Zhang X, Wennerberg E, Lorent J, Witt K, et al. 31st annual meeting and associated programs of the society for immunotherapy of cancer (SITC 2016): part one. J Immunother Cancer (2016) 4(Suppl 1):1–106. doi:10.1186/s40425-016-0172-7

351. Eissa JR, Naoe Y, Bustos-Villalobos I, Ichinose T, Tanaka M, Zhiwen W, et al. Genomic signature of the natural oncolytic herpes simplex virus HSV10 and its therapeutic role in preclinical and clinical trials. Front Oncol (2017) 7:149. doi:10.3389/fonc.2017.00149

352. Infante JR, Hansen AR, Pishvaian MJ, Man Chow IJ, McArthur GA, Bauer TM. A phase lb dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. J Clin Oncol (2016) 34(Suppl):abstr101. doi:10.1200/JCO.2016.34.15_suppl.101

353. Fury MG, Lipton A, Smith KM, Winston CB, Piśter DG. A phase-1 trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother (2013) 62(2):153–63. doi:10.1007/s00262-012-1357-5

354. Mahalingam D, Patel M, Sachdev J, Hart L, Halama N, Ramanathan R, et al. Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC). Ann Oncol (2016) 27(Suppl 2):ii105. doi:10.1093/annonc/mdw200.11

355. Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2015) 194(3):950–9. doi:10.4049/jimmunol.1401686

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Corraliza-Gorjón, Somovilla-Crespo, Santamaria, Garcia-Sanz and Kremer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
**APPENDIX**

**Key Concepts**

Antibody-dependent cell cytotoxicity (ADCC): the binding of an antibody to a cell surface antigen promotes the interaction of the natural killer cell with the Fc antibody fragment and triggers its cytotoxic response.

Adaptive immune response: its main function is to eliminate pathogens and fight cancer. Specifically recognizes antigen though receptors on the surface of T and B lymphocytes. It creates immunological memory, after the initial response to a given antigen, leads to an exacerbated response to subsequent encounters with the same antigen. This is the basis of vaccination.

Antibody-dependent phagocytosis (ADCP): the binding of an antibody to a cell surface antigen allows the opsonization of the cell and promotes its phagocytosis.

Combined therapy: therapy that combines different therapeutic approaches (i.e., chemotherapy, radiotherapy, small molecule drugs, vaccines, antibodies, etc.).

Complement-dependent cytotoxicity (CDC): the binding of an antibody to a cell surface antigen activates the complement cascade, resulting in the cell's death.

Immune checkpoint: there are checkpoints that receive negative signals from the tumor, inhibiting the antitumor immune response. These include the PD-1/PD-L1 axis (PD-1 receptor on the T cells and to PD-L1 on the tumor cells) and CTLA-4 (on T cells). Antibodies against these molecules (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, and ipilimumab) are able to inhibit these negative signals and promote the antitumor immune response.

Immunotherapy: therapeutic treatment that takes advantage of the immune system response.

Innate immune response: provides immediate defense against infection, on a non-specific manner, is not long-lasting and recognizes pathogens through generic receptors.

Therapeutic antibody: an antibody that can be used for therapeutic purposes, which is able to either act as antagonist, guide a drug toward the tumor cell, where it will act, or kill the tumor cell either directly or by activating immune response mechanisms (ADCC, CDC, and ADCP).

Vaccine: compounds inoculated in an organism to evoke a primary immune response, generating immunological memory able to protect against the antigen.